{
  "meta": {
    "title": "00077_Late_Night_Pyq_Pyt_Marathon_Pharma-4",
    "url": "https://brainandscalpel.vercel.app/00077-late-night-pyq-pyt-marathon-pharma-4-b4fbfb9e.html",
    "scrapedAt": "2025-11-29T17:25:23.471Z"
  },
  "questions": [
    {
      "id": 33858,
      "choices": [
        {
          "id": 135270,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 135271,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 135272,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        },
        {
          "id": 135273,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Drug of choice for acute rheumatic fever is?</span> <span style=\"font-size:12.0pt;\">(Fmge Jan 2024)</span></p>",
      "unique_key": "Q8209388",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056326,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Aspirin</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Aspirin is the drug of choice for acute rheumatic fever due to its efficacy in reducing inflammation and managing symptoms like arthritis and carditis, which are common in rheumatic fever. The other listed drugs are not used for this condition and are more specific to heart diseases and arrhythmias.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A.</strong> <strong>Digoxin:</strong> This medication is a cardiac glycoside, typically used in heart failure and certain arrhythmias. It is not used in the treatment of acute rheumatic fever.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong> <strong>Amiodarone:</strong> This is an antiarrhythmic medication used primarily for the treatment of various cardiac arrhythmias. It is not indicated for acute rheumatic fever.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D.</strong> <strong>Furosemide:</strong> Furosemide is a diuretic, often used in conditions like heart failure and hypertension. It is not a treatment for acute rheumatic fever.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Aspirin is an anti-inflammatory drug and is commonly used in the treatment of acute rheumatic fever, particularly for its anti-inflammatory effects in managing arthritis and carditis associated with rheumatic fever.</span></p>",
      "correct_choice_id": 135271,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6488,
      "choices": [
        {
          "id": 25921,
          "text": "<p><span style=\"font-size:12.0pt;\">Ivabradine</span></p>"
        },
        {
          "id": 25922,
          "text": "<p><span style=\"font-size:12.0pt;\">Ranolazine</span></p>"
        },
        {
          "id": 25923,
          "text": "<p><span style=\"font-size:12.0pt;\">Trimetazidine</span></p>"
        },
        {
          "id": 25924,
          "text": "<p><span style=\"font-size:12.0pt;\">Fasudil</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs acts by inhibiting the late sodium current in the heart? (NEET PG 2020)</span></p>",
      "unique_key": "Q6802639",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999939,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Ranolazine</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Ranolazine is an anti-anginal drug, that is a Fatty acid oxidation inhibitor (Another one being Trimetazidine), that acts by decreasing the oxygen demand of the heart by making it utilize glucose as the source of ATP.</span></li><li><span style=\"font-size:12.0pt;\">Ranolazine also acts on the late Na<sup>+</sup> channel in the heart, which helps in reducing the intracellular calcium concentration, thereby reducing the diastolic tension and the cardiac contractility.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Ivabradine</strong>: Ivabradine acts by selectively inhibiting the funny current (If) in the sinoatrial node, which reduces the heart rate. It does not inhibit the late sodium current.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Trimetazidine</strong>: Trimetazidine is also a metabolic modulator that shifts the heart's energy substrate preference from fatty acid oxidation to glucose oxidation, improving myocardial efficiency. However, it does not inhibit the late sodium current.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Fasudil</strong>: Fasudil is a Rho-kinase inhibitor that causes vasodilation, primarily used for conditions such as cerebral vasospasm and pulmonary hypertension. It does not affect the late sodium current.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ranolazine acts by inhibiting the late sodium current in the heart, which reduces intracellular calcium overload, decreases diastolic tension, and lowers myocardial oxygen demand, making it effective in the management of chronic angina.</span></p>",
      "correct_choice_id": 25922,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31810,
      "choices": [
        {
          "id": 127110,
          "text": "<p><span style=\"font-size:12pt;\">5-Aminosalicylic acid</span></p>"
        },
        {
          "id": 127111,
          "text": "<p><span style=\"font-size:12pt;\">5-Fluorouracil</span></p>"
        },
        {
          "id": 127112,
          "text": "<p><span style=\"font-size:12pt;\">Budesonide</span></p>"
        },
        {
          "id": 127113,
          "text": "<p><span style=\"font-size:12pt;\">6-Mercaptopurine</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A patient with ulcerative colitis is experiencing three episodes of bleeding in stools per day but is otherwise stable. What is the appropriate treatment for this patient? (INICET NOV 2023)</span></p>",
      "unique_key": "Q5712191",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999768,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) 5-Aminosalicylic acid.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">5-Aminosalicylic acid (5-ASA) is the first-line treatment for mild to moderate ulcerative colitis, especially in a stable patient who is experiencing active symptoms like bleeding. It works as an anti-inflammatory agent in the colon and is effective in inducing and maintaining remission.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. 5-Fluorouracil:</strong> This is a chemotherapeutic agent and is not used for treating ulcerative colitis. It's primarily used in cancer treatment.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Budesonide:</strong> While budesonide, a corticosteroid, is used in ulcerative colitis, it's generally reserved for more severe cases or when 5-ASA is ineffective. In a stable patient, it may not be the first choice.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. 6-Mercaptopurine:</strong> This is an immunosuppressant used in ulcerative colitis primarily for maintenance therapy or in patients who haven't responded to other treatments, not typically as a first-line treatment in a stable patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">5-Aminosalicylic acid (5-ASA) is the first-line treatment for mild to moderate ulcerative colitis and is effective in reducing inflammation and maintaining remission in stable patients experiencing active symptoms.</span></p>",
      "correct_choice_id": 127110,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31808,
      "choices": [
        {
          "id": 127102,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sumatriptan </span></span></p>"
        },
        {
          "id": 127103,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Promethazine </span></span></p>"
        },
        {
          "id": 127104,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Scopolamine </span></span></p>"
        },
        {
          "id": 127105,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Acetazolamide</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A person is preparing for a trip to Ladakh. Which of the following drugs should be used to prevent the onset of mountain sickness? (Fmge July 2023)</span></span></p>",
      "unique_key": "Q1547028",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056332,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D)</strong> <strong>Acetazolamide</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Acetazolamide is the recommended drug for the prevention of mountain sickness. It works by causing metabolic acidosis, which stimulates breathing, increasing oxygenation and helping the body adjust to the lower oxygen levels at high altitudes, such as those found in Ladakh.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Sumatriptan:</strong> This medication is used to treat migraine headaches, not for preventing mountain sickness.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Promethazine:</strong> Primarily used as an antihistamine and antiemetic, promethazine is not effective in preventing mountain sickness.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Scopolamine:</strong> Commonly used for motion sickness, scopolamine is not a recommended medication for preventing mountain sickness.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective: </strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acetazolamide is used to prevent mountain sickness because it induces metabolic acidosis, which stimulates increased breathing and oxygenation, aiding acclimatization to high altitudes.</span></span></p>",
      "correct_choice_id": 127105,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7092,
      "choices": [
        {
          "id": 28336,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1 month</span></span></span></p>"
        },
        {
          "id": 28337,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">3 months</span></span></span></p>"
        },
        {
          "id": 28338,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">No need to stop</span></span></span></p>"
        },
        {
          "id": 28339,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Can be stopped and conceived soon after stopping</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A lady who had undergone mastectomy for breast cancer is being treated with tamoxifen. How long should it be stopped for before she can conceive?</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span>&nbsp;(INICET MAY 2022)</p>",
      "unique_key": "Q5758754",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999953,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B. 3 months</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tamoxifen is a Selective Estrogen Receptor Modulator (SERM), which is used in Premenopausal women having ER +ve breast cancer, because of its anti-estrogenic action in the breast. It prevents the chance of recurrence of breast cancer after surgery. </span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The half-life of tamoxifen is approximately 5 to 7 days, but its active metabolites can persist in the body for several weeks. To minimize any risk to a potential pregnancy, it is recommended to stop tamoxifen at least 3 months before trying to conceive.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tamoxifen has teratogenic effects, such as craniofacial abnormalities and reproductive tract abnormalities. It is also stopped during lactation as it is secreted in breast milk. </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tamoxifen should be stopped for at least 3 months before attempting to conceive due to its long half-life and potential teratogenic effects. This ensures that the drug and its active metabolites are sufficiently cleared from the body, reducing the risk of harm to the fetus.</span></span></span></p>",
      "correct_choice_id": 28337,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6435,
      "choices": [
        {
          "id": 25709,
          "text": "<p><span style=\"font-size:12.0pt;\">Strontium ranelate</span></p>"
        },
        {
          "id": 25710,
          "text": "<p><span style=\"font-size:12.0pt;\">Ibandronate</span></p>"
        },
        {
          "id": 25711,
          "text": "<p><span style=\"font-size:12.0pt;\">Teriparatide</span></p>"
        },
        {
          "id": 25712,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcitonin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following acts by causing both decreased bone resorption and increased bone formation?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p>",
      "unique_key": "Q6202281",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056331,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Strontium ranelate</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Strontium ranelate is a unique agent used in the treatment of osteoporosis. It has a dual mode of action: it decreases bone resorption and simultaneously increases bone formation. This dual effect is beneficial in managing osteoporosis, as it helps to improve bone density and strength by promoting a balanced bone remodeling process.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Ibandronate:&nbsp;</strong>Ibandronate is a bisphosphonate that primarily acts by reducing bone resorption. It inhibits osteoclast activity, leading to decreased bone turnover and increased bone mineral density.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Teriparatide:&nbsp;</strong>Teriparatide is a recombinant form of parathyroid hormone (PTH) that primarily stimulates bone formation. It acts on osteoblasts, increasing their activity and promoting new bone formation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Calcitonin</strong>: Calcitonin decreases bone resorption by inhibiting osteoclast activity. It is used in the treatment of conditions like osteoporosis and Paget's disease but does not significantly promote bone formation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Strontium ranelate is unique among osteoporosis treatments in that it both decreases bone resorption and increases bone formation, making it a valuable option for improving bone health in patients with osteoporosis. Other drugs like ibandronate and calcitonin primarily focus on reducing bone resorption, while teriparatide promotes bone formation.</span></p>",
      "correct_choice_id": 25709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20919,
      "choices": [
        {
          "id": 83640,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibit extrinsic pathway</span></p>"
        },
        {
          "id": 83641,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits platelet aggregation</span></p>"
        },
        {
          "id": 83642,
          "text": "<p><span style=\"font-size:12.0pt;\">Enhance fibrin degradation</span></p>"
        },
        {
          "id": 83643,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibit clot formation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The mechanism of action of tissue plasminogen activator is: (NEET PG 2023)</span></p>",
      "unique_key": "Q2275137",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999962,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Enhance fibrin degradation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tissue plasminogen activators (tPA) converts plasminogen to plasmin that breaks&nbsp;the thrombus, which results in fibrinolysis of formed thrombus (thrombolysis).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Drugs in this class include:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">S – Streptokinase</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">U – Urokinase</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">R – Reteplase</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A – Alteplase</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">T – Tenecteplase</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Indication → Pulmonary embolism with hemodynamic instability</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute ischemic stroke</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute MI</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Overdose of thrombolytics</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">→ Leads to bleeding</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">→ Antidotes: Epsilon Amino Caproic Acid [EACA]</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tranexamic Acid</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Inhibit extrinsic pathway:&nbsp;</strong>This is not the mechanism of tPA. The extrinsic pathway involves the activation of clotting factors by tissue factor and is more related to clot formation rather than breakdown.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Inhibits platelet aggregation:&nbsp;</strong>This is not the mechanism of tPA. Platelet aggregation is inhibited by drugs like aspirin and clopidogrel, not by tPA.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Inhibit clot formation:&nbsp;</strong>This is not the mechanism of tPA. Inhibition of clot formation is achieved by anticoagulants like heparin and warfarin, whereas tPA is involved in clot breakdown.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tissue plasminogen activator (tPA) enhances fibrin degradation by converting plasminogen to plasmin, leading to the dissolution of blood clots.</span></p>",
      "correct_choice_id": 83642,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7053,
      "choices": [
        {
          "id": 28180,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Downregulation of CYP2C19</span></span></span></p>"
        },
        {
          "id": 28181,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Downregulation of CYP2D6</span></span></span></p>"
        },
        {
          "id": 28182,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Upregulation of CYP1A1</span></span></span></p>"
        },
        {
          "id": 28183,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Downregulation of CYP2E1</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of 45 year with history of ischemic stroke was started on clopidogrel, However, she had another attack of stroke after 6 months. Which of the following is likely to be responsible for the failure of clopidogrel in this patient? (INICET MAY 2021)</span></span></p>",
      "unique_key": "Q3096448",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999960,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Downregulation of CYP2C19</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clopidogrel is an antiplatelet drug used to prevent MI and stroke. The failure of clopidogrel in preventing a second stroke in a patient can be influenced by various factors, including genetic variations that affect drug metabolism. </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel is a prodrug that requires activation by CYP2C19. Genetic polymorphisms or downregulation of CYP2C19 can lead to reduced conversion of clopidogrel to its active form. This results in decreased antiplatelet activity and a higher risk of thrombotic events, such as stroke. Individuals with reduced function alleles of CYP2C19 are known as &quot;poor metabolizers,&quot; and in these patients, clopidogrel may be less effective.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Downregulation of CYP2D6</strong>: While CYP2D6 is important for the metabolism of many drugs, it is not primarily responsible for the activation of clopidogrel. Therefore, downregulation of CYP2D6 would not significantly impact clopidogrel&#39;s effectiveness.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Upregulation of CYP1A1</strong>: CYP1A1 is not involved in the metabolism of clopidogrel. Its upregulation would not affect the activation of clopidogrel or its therapeutic efficacy.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Downregulation of CYP2E1</strong>: CYP2E1 is involved in the metabolism of ethanol and certain other drugs but does not play a significant role in the activation of clopidogrel. Therefore, downregulation of CYP2E1 would not impact clopidogrel&#39;s effectiveness.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The failure of clopidogrel in preventing a second stroke in a patient may be due to the downregulation of CYP2C19. This enzyme is crucial for converting clopidogrel into its active form, and its reduced activity can lead to decreased antiplatelet effects and increased risk of thrombotic events.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/18/screenshot-2024-07-18-111759.png\" style=\"height:500px; width:1000px\" /></span></span></span></p>",
      "correct_choice_id": 28180,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6500,
      "choices": [
        {
          "id": 25969,
          "text": "<p><span style=\"font-size:12.0pt;\">Morphine</span></p>"
        },
        {
          "id": 25970,
          "text": "<p><span style=\"font-size:12.0pt;\">Diclofenac</span></p>"
        },
        {
          "id": 25971,
          "text": "<p><span style=\"font-size:12.0pt;\">Nefopam</span></p>"
        },
        {
          "id": 25972,
          "text": "<p><span style=\"font-size:12.0pt;\">Etoricoxib</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presented with biliary colic. The intern has administered an analgesic, following which the pain got aggravated. Which of the following could be responsible for the aggravation of the patient's symptoms? (NEET PG 2020)</span></p>",
      "unique_key": "Q1089394",
      "question_audio": null,
      "question_video": null,
      "map_id": 15178309,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Morphine</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Morphine can cause the contraction of the sphincter of Oddi, which is a muscular valve that controls the flow of bile and pancreatic juice into the small intestine.</span></li><li><span style=\"font-size:12.0pt;\">In patients with biliary colic, the contraction of the sphincter of Oddi can exacerbate the pain and lead to complications such as pancreatitis.</span></li><li><span style=\"font-size:12.0pt;\">Therefore, in patients with suspected biliary colic, it is important to use caution when administering morphine and to consider alternative analgesic medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or pethidine.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Diclofenac</strong>: Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that does not cause sphincter of Oddi contraction and is unlikely to aggravate biliary colic.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Nefopam</strong>: Nefopam is a non-opioid analgesic that does not affect the sphincter of Oddi and is not likely to aggravate biliary colic.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Etoricoxib</strong>: Etoricoxib is a selective COX-2 inhibitor, another type of NSAID, which does not cause contraction of the sphincter of Oddi and is not likely to aggravate biliary colic.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Morphine can exacerbate pain in biliary colic by causing contraction of the sphincter of Oddi. In patients with suspected biliary colic, alternative analgesic medications such as NSAIDs or pethidine should be considered to avoid worsening the condition.</span></p>",
      "correct_choice_id": 25969,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9773,
      "choices": [
        {
          "id": 39059,
          "text": "<p><span style=\"font-size:12.0pt;\">Vimentin</span></p>"
        },
        {
          "id": 39060,
          "text": "<p><span style=\"font-size:12.0pt;\">Tubulin</span></p>"
        },
        {
          "id": 39061,
          "text": "<p><span style=\"font-size:12.0pt;\">Desmin</span></p>"
        },
        {
          "id": 39062,
          "text": "<p><span style=\"font-size:12.0pt;\">Neurofilament</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not an intermediate filament?</span> (AIIMS MAY 2019)</p>",
      "unique_key": "Q9011249",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999954,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Tubulin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Tubulin is a part of microtubules and is not an intermediate filament</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The intermediate filaments comprise the major component of the cytoskeleton and consist of five major subgroups—vimentin, keratins, desmin, neurofilaments, and glial fibrillary acidic protein (GFAP)—and a small number of minor subgroups (e.g., nestin, peripherin).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/02/screenshot-2024-09-02-114628.png\" alt=\"\" width=\"1000\" height=\"457\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Vimentin</strong>: Vimentin is an intermediate filament protein commonly found in cells of mesenchymal origin. It helps maintain cellular integrity and provides resistance to stress.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Desmin</strong>: Desmin is an intermediate filament protein found predominantly in muscle cells. It is crucial for maintaining the structural integrity of muscle cells by linking the cytoskeletal network to the sarcomere.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Neurofilament</strong>: Neurofilaments are intermediate filaments found in neurons. They are important for maintaining the shape and strength of nerve cells and play a role in the conduction of nerve impulses.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tubulin is not an intermediate filament; it is a protein that forms microtubules, which are essential for cell shape, motility, and division. Intermediate filaments, such as vimentin, desmin, and neurofilaments, provide mechanical support and structural integrity to cells.</span></p>",
      "correct_choice_id": 39060,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31862,
      "choices": [
        {
          "id": 127318,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is related to the volume of distribution of the drug. </span></span></p>"
        },
        {
          "id": 127319,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is related to the P-drug concept. </span></span></p>"
        },
        {
          "id": 127320,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is related to the metabolism of the drug in the blood. </span></span></p>"
        },
        {
          "id": 127321,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is related to clinical trials of the drug.</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is correct regarding the STEP (Safety, Tolerability, Efficacy, and Price) criteria concerning drugs? (Fmge July 2023)</span></span></p>",
      "unique_key": "Q8438685",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056323,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B) It is related to the P-drug concept.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The STEP criteria are related to the P-drug concept. P-drug refers to Personal drug selection and usage, emphasizing the choice of drugs based on Safety, Tolerability, Efficacy, and Price, making it a comprehensive approach to prescribing medication.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong> The volume of distribution of a drug is a pharmacokinetic parameter, not directly related to the STEP criteria.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong> The metabolism of the drug in the blood is also a pharmacokinetic aspect, not primarily associated with STEP.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong> While clinical trials evaluate aspects of safety and efficacy, the STEP criteria encompass broader aspects, including tolerability and price, as part of the P-drug concept.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective: </strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The STEP criteria (Safety, Tolerability, Efficacy, and Price) are integral to the P-drug concept, guiding healthcare professionals in selecting the most appropriate medication for their patients based on a comprehensive evaluation of these factors.</span></span></p>",
      "correct_choice_id": 127319,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44823,
      "choices": [
        {
          "id": 178939,
          "text": "<p><span style=\"font-size:12pt;\">Syrup Dextromethorphan with bromhexine</span></p>"
        },
        {
          "id": 178940,
          "text": "<p><span style=\"font-size:12pt;\">Syrup Codeine</span></p>"
        },
        {
          "id": 178941,
          "text": "<p><span style=\"font-size:12.0pt;\">Syrup dextromethorphan</span></p>"
        },
        {
          "id": 178942,
          "text": "<p><span style=\"font-size:12pt;\">Syrup bromhexine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">A 30-year-old patient presented with fever, cough and tenacious white sputum. Which of the following should be used for treatment? (INICET MAY 2024)</span></p>",
      "unique_key": "Q2531058",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999955,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Syrup bromhexine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Bromhexine is a mucolytic agent that helps to thin and loosen mucus, making it easier to expectorate. This is particularly useful for patients with a productive cough and tenacious sputum, as it facilitates the clearance of mucus from the airways.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;A.</strong>&nbsp;<strong>Syrup Dextromethorphan with bromhexine</strong>: Dextromethorphan is a cough suppressant, and bromhexine is a mucolytic. While bromhexine can help thin the mucus, dextromethorphan is not recommended for productive coughs as it suppresses the cough reflex, potentially leading to mucus retention.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;B.</strong>&nbsp;<strong>Syrup Codeine</strong>: Codeine is an opioid cough suppressant. Like dextromethorphan, it is not suitable for productive coughs as it suppresses the cough reflex, which can lead to mucus accumulation in the airways.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C.</strong>&nbsp;<strong>Syrup Dextromethorphan</strong>: Dextromethorphan is a cough suppressant that is not appropriate for productive coughs, as it can prevent the clearing of mucus from the respiratory tract.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In summary, syrup bromhexine is the most appropriate choice for treating a patient with fever, cough, and tenacious white sputum, as it helps to thin and loosen the mucus, making it easier to clear from the respiratory tract.</span></p>",
      "correct_choice_id": 178942,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 34043,
      "choices": [
        {
          "id": 136007,
          "text": "<p><span style=\"font-size:12.0pt;\">Adipose</span></p>"
        },
        {
          "id": 136008,
          "text": "<p><span style=\"font-size:12.0pt;\">RBC</span></p>"
        },
        {
          "id": 136009,
          "text": "<p><span style=\"font-size:12.0pt;\">Pancreas</span></p>"
        },
        {
          "id": 136010,
          "text": "<p><span style=\"font-size:12.0pt;\">Brain</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Insulin independent absorption occurs in all except: (INICET NOV 2023)</span></p>",
      "unique_key": "Q6213718",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999943,
      "difficulty_level": "intermediate",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Adipose</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Glucose uptake in adipose tissue is insulin-dependent, primarily using GLUT4 transporters activated by insulin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. RBC:</strong> Red Blood Cells utilize GLUT1 transporters for glucose absorption, which is insulin-independent and crucial for their energy needs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Pancreas:</strong> While the pancreas plays a role in insulin production, its glucose absorption is not predominantly insulin-independent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Brain:</strong> The brain absorbs glucose independently of insulin, using GLUT3 transporters, essential for its constant energy requirements.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Glucose uptake in adipose tissue is insulin-dependent, while RBCs, pancreas, and brain utilize insulin-independent mechanisms for glucose absorption.</span></p>",
      "correct_choice_id": 136007,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6489,
      "choices": [
        {
          "id": 25925,
          "text": "<p><span style=\"font-size:12.0pt;\">Tamsulosin</span></p>"
        },
        {
          "id": 25926,
          "text": "<p><span style=\"font-size:12.0pt;\">Bethanechol</span></p>"
        },
        {
          "id": 25927,
          "text": "<p><span style=\"font-size:12.0pt;\">Terazosin</span></p>"
        },
        {
          "id": 25928,
          "text": "<p><span style=\"font-size:12.0pt;\">Methacholine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with diabetes and COPD developed post-operative urinary retention. Which of the following drugs can be used for short-term treatment of the condition? (NEET PG 2020)</span></p>",
      "unique_key": "Q5057938",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999956,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Bethanechol</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bethanechol is a muscarinic agonist that stimulates the bladder's detrusor muscle to contract, thereby promoting urination. It is specifically used in the treatment of post-operative urinary retention. However, caution is required when prescribing bethanechol to patients with COPD or asthma due to its potential to cause bronchoconstriction through its action on M3 receptors in the bronchus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Tamsulosin</strong>: Tamsulosin is an alpha-1 adrenergic blocker primarily used to treat urinary symptoms associated with benign prostatic hyperplasia (BPH). It is not used for post-operative urinary retention.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Terazosin</strong>: Terazosin is another alpha-1 adrenergic blocker used for BPH and hypertension. It does not have a role in treating post-operative urinary retention.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Methacholine</strong>: Methacholine is a muscarinic receptor agonist used in the diagnosis of asthma by performing the bronchial challenge test. It is not used for treating post-operative urinary retention and can precipitate bronchoconstriction, making it unsuitable for patients with COPD.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bethanechol is used for the short-term treatment of post-operative urinary retention by stimulating the bladder's detrusor muscle. Despite its potential to cause bronchoconstriction in patients with COPD, it is the only suitable drug among the given options for this condition.</span></p>",
      "correct_choice_id": 25926,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6473,
      "choices": [
        {
          "id": 25861,
          "text": "<p><span style=\"font-size:12.0pt;\">Interferes with DNA and RNA synthesis</span></p>"
        },
        {
          "id": 25862,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of ergosterol synthesis</span></p>"
        },
        {
          "id": 25863,
          "text": "<p><span style=\"font-size:12.0pt;\">Forms pores in fungal membranes</span></p>"
        },
        {
          "id": 25864,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits epoxidation of squalene in fungi</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the mechanism of triazoles? (NEET PG 2019)</span></p>",
      "unique_key": "Q3608111",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999963,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Inhibition of ergosterol synthesis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Triazoles include drugs like Itraconazole , Voriconazole , Fluconazole and Posaconazole. They are antifungal drugs that act by inhibiting 14-α demethylase , which prevents the conversion of Lanosterol to Ergosterol , thereby inhibiting the fungal cell wall synthesis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Interferes with DNA and RNA synthesis:&nbsp;</strong>This mechanism is characteristic of nucleoside analogues such as flucytosine, which are incorporated into RNA and disrupt protein synthesis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Forms pores in fungal membranes:&nbsp;</strong>This mechanism is characteristic of polyenes, such as amphotericin B and nystatin, which bind to ergosterol and form pores in the fungal cell membrane.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Inhibits epoxidation of squalene in fungi:&nbsp;</strong>This mechanism is characteristic of allylamines, such as terbinafine and naftifine, which inhibit the enzyme squalene epoxidase, leading to ergosterol depletion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/16/screenshot-2024-07-16-182250.png\" alt=\"\" width=\"1000\" height=\"376\"></p>",
      "correct_choice_id": 25862,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52117,
      "choices": [
        {
          "id": 207969,
          "text": "<p><span style=\"font-size:12.0pt;\">a-2, b-1, c-4, d-3</span></p>"
        },
        {
          "id": 207970,
          "text": "<p><span style=\"font-size:12.0pt;\">a-3, b-1, c-4, d-2</span></p>"
        },
        {
          "id": 207971,
          "text": "<p><span style=\"font-size:12.0pt;\">a-2, b-4, c-1, d-3</span></p>"
        },
        {
          "id": 207972,
          "text": "<p><span style=\"font-size:12.0pt;\">a-1, b-2, c-3, d-4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following:&nbsp;</span>(INICET MAY 2024)</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/18/screenshot-2024-07-18-154118.png\" alt=\"\" width=\"500\" height=\"202\"></span></p>",
      "unique_key": "Q2643761",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999938,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) a-3, b-1, c-4, d-2</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>A-3. Rotavirus</strong> is a member of the Reoviridae family, which is an exception among RNA viruses because it has double-stranded RNA<strong> (dsRNA).</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>B-1. SARS-CoV-2</strong> is a coronavirus, which is a single-stranded RNA <strong>(ssRNA) </strong>virus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>C-4. Parvovirus</strong> is a unique DNA virus because it has single-stranded DNA <strong>(ssDNA).</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>D-2. HPV (Human Papillomavirus)</strong> belongs to the Papillomaviridae family and has double-stranded DNA <strong>(dsDNA).</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Understanding the nucleic acid composition of viruses is crucial. Rotavirus has dsRNA, SARS-CoV-2 has ssRNA, Parvovirus has ssDNA, and HPV has dsDNA.</span></p>",
      "correct_choice_id": 207970,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33854,
      "choices": [
        {
          "id": 135254,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Chloroquine plus primaquine</span></p>"
        },
        {
          "id": 135255,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Quinine</span></p>"
        },
        {
          "id": 135256,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Artemisinin based combination therapy</span></p>"
        },
        {
          "id": 135257,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Doxycycline</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 2-month pregnant female presented with Plasmodium vivax malaria. Which of the following is the appropriate treatment for this patient?</span> <span style=\"font-size:12.0pt;\">(Fmge Jan 2024)</span></p>",
      "unique_key": "Q7962807",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999957,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Quinine</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">For a pregnant woman with Plasmodium vivax malaria, Chloroquine alone is the appropriate choice. Primaquine is contraindicated during pregnancy due to potential risks to the fetus. Quinine is normally used for Plasmodium falciparum malaria but can be used in P. vivax malaria also if other options are not available. It is safe in pregnancy. ACTs are generally avoided in the first trimester, and Doxycycline is contraindicated in pregnancy. Therefore, Chloroquine, without Primaquine, is the safest and most effective option in this case. However, as it is not in the options, so the next best option i.e. quinine will be the answer.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Chloroquine plus Primaquine:</strong> Chloroquine is considered safe and effective for the treatment of Plasmodium vivax malaria during pregnancy. However, primaquine is contraindicated in pregnancy due to the risk of hemolytic anemia in the fetus, especially if there is G6PD deficiency, which cannot be tested for in the fetus.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Artemisinin-Based Combination Therapy (ACT):</strong> While ACTs are very effective in treating Plasmodium falciparum malaria, their safety profile in the first trimester of pregnancy is not well-established. Generally, they are avoided in the first trimester unless no other options are available.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Doxycycline:</strong> Doxycycline is contraindicated in pregnancy due to the risk of interfering with bone and teeth development in the fetus.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Quinine is often used as a treatment for malaria during pregnancy, especially if other options are not available or suitable. However, it is usually more associated with the treatment of Plasmodium falciparum rather than Plasmodium vivax.</span></p>",
      "correct_choice_id": 135255,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24711,
      "choices": [
        {
          "id": 98805,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ratio of the median lethal dose to the median effective dose in an individual. </span></span></span></p>"
        },
        {
          "id": 98806,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The range of doses at which a drug is effective without causing significant adverse effects. </span></span></span></p>"
        },
        {
          "id": 98807,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ratio of the median lethal dose to the median effective dose in a population. </span></span></span></p>"
        },
        {
          "id": 98808,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dosage at which a drug is both safe and effective in the majority of patients.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clinical </span><span style=\"font-size:12.0pt\">Therapeutic Index of a drug is best described as:&nbsp;</span></span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q3673197",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999950,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. The ratio of the median lethal dose to the median effective dose in a population.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Clinical Therapeutic Index of a drug is best described as the ratio of the median lethal dose (LD50) to the median effective dose (ED50). Both LD50 and ED50 are calculated by checking different doses in a population. </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It represents the margin of safety of a drug. A higher Clinical Therapeutic Index indicates that a drug has a greater margin of safety, and can be given at higher doses without causing significant adverse effects. </span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Clinical Therapeutic Index is an important consideration in the development and use of new medications, and helps healthcare providers determine the appropriate dose for individual patients.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:24px; text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. The ratio of the median lethal dose to the median effective dose in an individual</span></strong><span style=\"font-size:12.0pt\">: This description is incorrect because the therapeutic index is determined based on population data, not individual data.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. The range of doses at which a drug is effective without causing significant adverse effects</span></strong><span style=\"font-size:12.0pt\">: This describes the therapeutic window or therapeutic range, not the therapeutic index.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. The dosage at which a drug is both safe and effective in the majority of patients</span></strong><span style=\"font-size:12.0pt\">: This is a general description of an effective and safe dosage regimen but does not specifically describe the therapeutic index.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Clinical Therapeutic Index of a drug is the ratio of the median lethal dose (LD50) to the median effective dose (ED50) in a population, representing the drug&#39;s margin of safety. A higher Therapeutic Index indicates a greater margin of safety.</span></span></span></p>",
      "correct_choice_id": 98807,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24714,
      "choices": [
        {
          "id": 98817,
          "text": "<p><span style=\"font-size:12.0pt;\">T790M mutation</span></p>"
        },
        {
          "id": 98818,
          "text": "<p><span style=\"font-size:12.0pt;\">L858R mutation</span></p>"
        },
        {
          "id": 98819,
          "text": "<p><span style=\"font-size:12.0pt;\">T890M mutation</span></p>"
        },
        {
          "id": 98820,
          "text": "<p><span style=\"font-size:12.0pt;\">M790T mutation</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A patient is diagnosed with non-small cell lung carcinoma (NSCLC). Molecular testing reveals a specific mutation in the EGFR gene. The oncologist is considering using targeted therapy. For which of the following EGFR mutations is Osimertinib most appropriately used to treat non-small cell lung carcinoma?&nbsp;</span>(INICET MAY 2023)</p>",
      "unique_key": "Q7296059",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999772,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. T790M mutation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Osimertinib</strong> is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is particularly effective in treating non-small cell lung carcinoma (NSCLC) patients who have developed resistance to first-generation EGFR inhibitors (such as gefitinib or erlotinib) due to the T790M mutation in the EGFR gene. This mutation is a common mechanism of acquired resistance, and Osimertinib is specifically designed to target it.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;<strong>L858R mutation</strong> is another common EGFR mutation seen in NSCLC. Although Osimertinib can also be used for L858R mutations, it is not specifically indicated as the primary treatment for this mutation. First-generation EGFR inhibitors like gefitinib or erlotinib are often used for L858R mutations.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C</strong>.&nbsp;<strong>T890M mutation</strong> and <strong>Option D</strong>. <strong>M790T mutation</strong> are not recognized mutations associated with EGFR in the context of NSCLC, and there is no evidence to suggest that Osimertinib is used for these mutations.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/02/screenshot-2023-12-02-110037.png\" alt=\"\" width=\"1000\" height=\"457\"></span></p>",
      "correct_choice_id": 98817,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51450,
      "choices": [
        {
          "id": 205317,
          "text": "<p style=\"margin-left:-6px;\"><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        },
        {
          "id": 205318,
          "text": "<p style=\"margin-left:-6px;\"><span style=\"font-size:12.0pt;\">Canagliflozin</span></p>"
        },
        {
          "id": 205319,
          "text": "<p style=\"margin-left:-6px;\"><span style=\"font-size:12.0pt;\">Glipizide</span></p>"
        },
        {
          "id": 205320,
          "text": "<p><span style=\"font-size:12.0pt;\">Pioglitazone</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 60-year-old female patient, who has been on anti-diabetic therapy for the last 10 years, has experienced three episodes of vaginal Candida infection in the past two months. Which of the following anti-diabetic drugs should be avoided in this patient? (FMGE JULY 2024)</span></p>",
      "unique_key": "Q7361546",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056329,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Canagliflozin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Canagliflozin belongs to the class of drugs called <strong>SGLT2 inhibitors</strong>. These drugs work by increasing glucose excretion in the urine. While this helps lower blood sugar levels, it also creates an environment in the urogenital tract that is favorable for the growth of yeast like Candida, leading to increased risk of vaginal yeast infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option</strong> <strong>A. Metformin:</strong>&nbsp; Metformin is a biguanide that works by decreasing glucose production in the liver and improving insulin sensitivity. It does not increase the risk of yeast infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Glipizide:</strong> Glipizide is a sulfonylurea that stimulates the pancreas to release more insulin. It does not have a direct impact on the urogenital tract or increase the risk of yeast infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option</strong> <strong>D. Pioglitazone:</strong> Pioglitazone is a thiazolidinedione that improves insulin sensitivity. It does not affect glucose levels in the urine and is not associated with an increased risk of yeast infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>SGLT2 inhibitors (drugs ending in \"-gliflozin\" - Canagliflozin, Dapagliflozin, Empagliflozin)</strong> can increase the risk of urogenital infections, including vaginal candidiasis, due to increased glucose excretion in the urine. They should be used with caution or avoided in patients prone to such infections.</span></p>",
      "correct_choice_id": 205318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6935,
      "choices": [
        {
          "id": 27708,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased CAMP</span></p>"
        },
        {
          "id": 27709,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulation of guanylyl cyclase</span></p>"
        },
        {
          "id": 27710,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium channel blockage</span></p>"
        },
        {
          "id": 27711,
          "text": "<p><span style=\"font-size:12.0pt;\">K+ channel opener</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the mechanism of action of sodium nitroprusside? (AIIMS NOV 2018)</span></p>",
      "unique_key": "Q1796801",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056330,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Stimulation of guanylyl cyclase</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Sodium nitroprusside is a potent vasodilator that works by stimulating guanylyl cyclase. When sodium nitroprusside enters the bloodstream, it rapidly releases nitric oxide (NO). This NO then activates guanylyl cyclase in vascular smooth muscle cells. The activation of guanylyl cyclase increases the conversion of GTP to cyclic GMP (cGMP). Elevated levels of cGMP lead to the dephosphorylation of myosin light chains, resulting in relaxation of vascular smooth muscle and subsequent vasodilation. This mechanism effectively reduces blood pressure and is used in the management of hypertensive emergencies and severe heart failure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Increased cAMP:&nbsp;</strong>Drugs that increase cAMP, such as beta-adrenergic agonists, work through different mechanisms involving the activation of adenylate cyclase, not guanylyl cyclase. cAMP primarily mediates actions like increased heart rate and bronchodilation, which is not the primary action of sodium nitroprusside.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Calcium channel blockage:&nbsp;</strong>Calcium channel blockers, such as verapamil and diltiazem, inhibit the influx of calcium ions into cardiac and smooth muscle cells, leading to muscle relaxation and vasodilation. Sodium nitroprusside does not act through this pathway.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. K+ channel opener:&nbsp;</strong>Potassium channel openers, such as minoxidil, work by hyperpolarizing the cell membrane, leading to relaxation of vascular smooth muscle. This is not the mechanism of action of sodium nitroprusside.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Sodium nitroprusside acts by stimulating guanylyl cyclase, which leads to an increase in cGMP, causing relaxation of vascular smooth muscle and vasodilation. This makes it effective in rapidly reducing blood pressure in hypertensive emergencies.</span></p>",
      "correct_choice_id": 27709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31807,
      "choices": [
        {
          "id": 127098,
          "text": "<p><span style=\"font-size:12pt;\">Hydroxyurea</span></p>"
        },
        {
          "id": 127099,
          "text": "<p><span style=\"font-size:12pt;\">Methotrexate plus leucovorin</span></p>"
        },
        {
          "id": 127100,
          "text": "<p><span style=\"font-size:12pt;\">Methionine</span></p>"
        },
        {
          "id": 127101,
          "text": "<p><span style=\"font-size:12pt;\">Eltrombopag</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following drugs is used to prevent painful vaso-occlusive crises and decrease long-term complications in sickle cell anemia? (INICET NOV 2023)</span></p>",
      "unique_key": "Q3783724",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999959,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Hydroxyurea.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Hydroxyurea is widely used in the management of sickle cell anemia. It helps to increase the concentration of fetal hemoglobin (HbF) in the bloodstream, which is less likely to participate in the sickling process that characterizes sickle cell disease. By reducing the sickling of red blood cells, hydroxyurea lowers the incidence of vaso-occlusive crises that cause pain and can lead to organ damage. Additionally, the drug has been shown to have a positive impact on the long-term complications associated with sickle cell anemia, including reducing the risk of stroke and other serious events.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Methotrexate plus leucovorin:</strong> This combination is not used for sickle cell anemia. Methotrexate is primarily used in the treatment of certain cancers and autoimmune diseases, and leucovorin is given to mitigate the side effects of methotrexate.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Methionine:</strong> Methionine is an essential amino acid that is not used to treat sickle cell anemia or its complications. It has no role in preventing vaso-occlusive crises. Rather L-glutamine is the amino acid that is used in sickle cell disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Eltrombopag:</strong> Eltrombopag is a medication that stimulates platelet production and is used in conditions like chronic immune thrombocytopenia. It is not indicated for the treatment or prevention of complications in sickle cell anemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Hydroxyurea is the primary medication used to prevent painful vaso-occlusive crises and decrease long-term complications in sickle cell anemia by increasing the concentration of fetal hemoglobin (HbF).</span></p>",
      "correct_choice_id": 127098,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65029,
      "choices": [
        {
          "id": 259293,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypokalemia increases the risk of digoxin toxicity.</span></p>"
        },
        {
          "id": 259294,
          "text": "<p><span style=\"font-size:12.0pt;\">The earliest manifestation of digoxin toxicity is gastrointestinal symptoms.</span></p>"
        },
        {
          "id": 259295,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum digoxin levels always correlate with toxicity.</span></p>"
        },
        {
          "id": 259296,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperkalemia is commonly seen in advanced digoxin toxicity.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements about digoxin toxicity is false? (Twisted PYQ)</span></p>",
      "unique_key": "Q6490121",
      "question_audio": null,
      "question_video": null,
      "map_id": 15323666,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Serum digoxin levels always correlate with toxicity.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Serum digoxin levels <strong>do not always correlate</strong> with toxicity because of its large volume of distribution (~450L). While elevated serum levels can indicate toxicity, clinical symptoms and signs such as arrhythmias, gastrointestinal disturbances, and neurological changes may occur even at normal serum levels, particularly in individuals with altered sensitivity (e.g., hypokalemia or renal impairment).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A: Hypokalemia increases the risk of digoxin toxicity</strong> – Hypokalemia increases the binding of digoxin to the Na+/K+ ATPase, thereby enhancing its toxic effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B: The earliest manifestation of digoxin toxicity is gastrointestinal symptoms</strong> – Nausea, vomiting, and abdominal pain are typically the earliest signs of digoxin toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D: Hyperkalemia is commonly seen in advanced digoxin toxicity</strong> – Hyperkalemia occurs due to Na+/K+ ATPase inhibition, leading to an inability to transport potassium into cells and its accumulation in the blood.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Digoxin toxicity can manifest with nonspecific symptoms and does not always correlate with serum levels. Understanding the interplay of electrolyte imbalances, particularly hypokalemia, and digoxin's mechanism of action is key to recognizing and managing toxicity effectively.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference: - KDT 8<sup>TH</sup>/560</strong></span></p>",
      "correct_choice_id": 259295,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9772,
      "choices": [
        {
          "id": 39055,
          "text": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Herpes virus</span></span></span></p>"
        },
        {
          "id": 39056,
          "text": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Verruca vulgaris</span></span></span></p>"
        },
        {
          "id": 39057,
          "text": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Molluscum contagiosum</span></span></span></p>"
        },
        {
          "id": 39058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lichen planus</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old male with skin-colored umbilicated papules. Microscopy is as shown below. The most likely diagnosis is: </span></span>(AIIMS MAY 2019)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/922.jpg\" style=\"height:226px; width:300px\" /></span></span></p>",
      "unique_key": "Q8423014",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999937,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Molluscum contagiosum</span></strong> </span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The given picture shows intracytoplasmic molluscum bodies (staining purple-pink) within the keratinocytes.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Molluscum contagiosum is a common self-limiting contagious lesion caused by a poxvirus which is a DNA virus. It is more common in children and young adults. Infection is acquired by direct contact. Clinically, the lesions are often multiple, discrete, waxy, papules, about 5 mm in diameter and are seen more frequently on the face and trunk</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tzanck smear shows intracytoplasmic molluscum bodies (<strong>Henderson-Patterson bodies), the largest known inclusion bodies (30-35 m).</strong></span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/923.jpg\" style=\"height:332px; width:417px\" /></strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Individual lesions are firm, pruritic, pink to skin-colored <strong>umbilicated papules</strong> (shown below). A curd-like material can be expressed from the central umbilication</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/924.jpg\" style=\"height:312px; width:400px\" /></span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Herpes virus</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Herpes simplex virus (HSV) infections typically present with grouped vesicles on an erythematous base, which then progress to pustules, ulcers, and crusts. The histology usually shows multinucleated giant cells with intranuclear inclusions on a Tzanck smear, not the intracytoplasmic molluscum bodies seen in this case.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Verruca vulgaris</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Also known as common warts, verruca vulgaris is caused by the human papillomavirus (HPV). These lesions are typically hyperkeratotic, exophytic papules with a rough surface. Histologically, they show papillomatosis, hyperkeratosis, and koilocytosis (vacuolated cells with a halo around the nucleus). These features are distinct from the molluscum bodies seen in Molluscum contagiosum.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Lichen planus</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Lichen planus is an inflammatory condition that presents with pruritic, polygonal, flat-topped, violaceous papules, often with Wickham striae (fine white lines) on the surface. Histologically, it shows a band-like lymphocytic infiltrate at the dermoepidermal junction, hypergranulosis, and saw-toothing of the rete ridges. These findings are not consistent with the histological image provided, which shows molluscum bodies.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Molluscum contagiosum is characterized by the presence of intracytoplasmic<strong> </strong>molluscum bodies (Henderson-Patterson bodies) within keratinocytes, and it presents clinically as skin-colored, umbilicated papules.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Robbins and Cotran pathologic basis of disease, 8<sup>th</sup> edition, Pg 1940</span></strong></span></span></p>",
      "correct_choice_id": 39057,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6513,
      "choices": [
        {
          "id": 26021,
          "text": "<p><span style=\"font-size:12.0pt;\">Clearance / Plasma concentration</span></p>"
        },
        {
          "id": 26022,
          "text": "<p><span style=\"font-size:12.0pt;\">Clearance x Plasma concentration</span></p>"
        },
        {
          "id": 26023,
          "text": "<p><span style=\"font-size:12.0pt;\">Clearance x Loading dose</span></p>"
        },
        {
          "id": 26024,
          "text": "<p><span style=\"font-size:12.0pt;\">Clearance / Loading dose</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old male patient is undergoing chronic medication therapy for a long-term condition. The healthcare team wants to maintain a specific steady-state plasma concentration of the drug. What formula should be used to calculate the maintenance dose rate of the drug for this patient? (NEET PG 2021)</span></p>",
      "unique_key": "Q8700776",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999945,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Clearance x Plasma concentration</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The formula for the maintenance dose rate (MD) of a drug is generally expressed as:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Maintenance&nbsp;Dose&nbsp;Rate&nbsp;(MD) = Clearance&nbsp;(CL) × Desired&nbsp;Plasma&nbsp;Concentration&nbsp;(Cp)&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This formula aims to achieve a steady-state concentration of the drug in the bloodstream. By multiplying the clearance rate by the desired plasma concentration, you get the rate at which the drug should be administered to maintain that desired concentration.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Note –</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The loading dose is designed to quickly achieve the desired therapeutic level, whereas the maintenance dose sustains that level over time.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The formula for calculating the maintenance dose rate (MD) of a drug is:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Maintenance&nbsp;Dose&nbsp;Rate&nbsp;(MD) = Clearance&nbsp;(CL)<strong>×</strong>Desired&nbsp;Plasma&nbsp;Concentration&nbsp;(Cp)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This formula is used to achieve and maintain a specific steady-state plasma concentration of the drug</span></p>",
      "correct_choice_id": 26022,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6411,
      "choices": [
        {
          "id": 25613,
          "text": "<p><span style=\"font-size:12.0pt;\">Bran</span></p>"
        },
        {
          "id": 25614,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Psyllium</span></p>"
        },
        {
          "id": 25615,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Senna</span></p>"
        },
        {
          "id": 25616,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Methylcellulose</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A colonoscopy on an 80-year-old patient revealed brownish pigmented lesions, as shown below. He admitted to using laxatives on a regular basis. Which of the following laxatives is most likely to be the source of this problem?</span><span style=\"font-size:10.5pt;\"> </span><span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/16/screenshot-2024-07-16-125141.png\" alt=\"\" width=\"300\" height=\"278\"></span></p>",
      "unique_key": "Q3632852",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999771,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Senna</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The given image shows the colonoscopy finding of melanosis coli.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The use of stimulant purgatives like Senna , Cascara Sagrada and Bisacodyl can lead to the development of melanosis coli. Also they should not be used for more than 10 days due to the risk of developing atonic colon.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Bran:&nbsp;</strong>Bran is a bulk-forming laxative that increases stool bulk and promotes regular bowel movements. It does not cause melanosis coli.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Psyllium:&nbsp;</strong>Psyllium is another bulk-forming laxative that absorbs water into the stool, making it easier to pass. It does not lead to melanosis coli.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Methylcellulose:&nbsp;</strong>Methylcellulose is a bulk-forming fiber laxative that works by absorbing water and increasing stool bulk. It is not associated with melanosis coli.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Chronic use of stimulant laxatives like Senna can lead to melanosis coli, characterized by brownish-black pigmentation of the colonic mucosa seen on colonoscopy.</span></p>",
      "correct_choice_id": 25615,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33859,
      "choices": [
        {
          "id": 135274,
          "text": "<p><span style=\"font-size:12.0pt;\">Blockade of Na-Cl symporter</span></p>"
        },
        {
          "id": 135275,
          "text": "<p><span style=\"font-size:12.0pt;\">Blockade of Na K 2Cl symporter</span></p>"
        },
        {
          "id": 135276,
          "text": "<p><span style=\"font-size:12.0pt;\">Blockade of aldosterone receptors</span></p>"
        },
        {
          "id": 135277,
          "text": "<p><span style=\"font-size:12.0pt;\">Blockade of epithelial sodium channels</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following is the mechanism of action of thiazides in DCT?</span> <span style=\"font-size:12.0pt;\">(Fmge Jan 2024)</span></p>",
      "unique_key": "Q4096308",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056334,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. A) Blockade of Na-Cl Symporter</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Thiazide diuretics act by blocking the sodium-chloride symporter in the distal convoluted tubule of the kidney. This action leads to decreased reabsorption of sodium and chloride, resulting in increased excretion of these ions along with water, thereby producing a diuretic effect.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B.</strong> <strong>Blockade of Na-K-2Cl Symporter:</strong> This is the mechanism of action of loop diuretics like furosemide, not thiazides. Loop diuretics inhibit the sodium-potassium-2 chloride symporter in the thick ascending limb of the loop of Henle.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong> <strong>Blockade of Aldosterone Receptors:</strong> This describes the mechanism of action of spironolactone and eplerenone, which are aldosterone antagonists. They work in the collecting ducts of the kidneys.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D.</strong> <strong>Blockade of Epithelial Sodium Channels:</strong> This is the mechanism of action of potassium-sparing diuretics like amiloride and triamterene, which act on the collecting ducts of the kidneys.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Thiazide diuretics primarily work by inhibiting the sodium-chloride symporter in the distal convoluted tubule of the kidney. This inhibition reduces sodium reabsorption, leading to increased excretion of sodium and water, thereby lowering blood pressure and reducing edema.</span></p>",
      "correct_choice_id": 135274,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57291,
      "choices": [
        {
          "id": 228541,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin</span></span></p>"
        },
        {
          "id": 228542,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low Molecular Weight Heparin (LMWH)</span></span></p>"
        },
        {
          "id": 228543,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apixaban</span></span></p>"
        },
        {
          "id": 228544,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fondaparinux</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman at 30 weeks of gestation is diagnosed with deep vein thrombosis (DVT). Which of the following is the most appropriate for this patient for prophylaxis? (NEET PG 2024)</span></span></span></p>",
      "unique_key": "Q1768268",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056328,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Low Molecular Weight Heparin (LMWH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During pregnancy, the choice of anticoagulant therapy is crucial due to the risks associated with both the mother and the developing fetus<strong>. Low Molecular Weight Heparin (LMWH) is the drug of choice for anticoagulation in pregnancy across all trimesters</strong>. It is preferred because it does not cross the placenta, making it safe for the fetus, and it has a lower risk of causing bleeding complications compared to other anticoagulants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this specific case of a woman at 30 weeks of gestation diagnosed with DVT, LMWH is the most appropriate choice for prophylaxis. Warfarin, although sometimes used in the second trimester, is generally avoided due to its teratogenic effects, particularly during the first trimester and closer to delivery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Newer anticoagulants like Apixaban and Fondaparinux are not typically recommended during pregnancy due to insufficient evidence of safety and potential risks.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Warfarin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Warfarin can be used during the second trimester up to 36 weeks if necessary. However, it is typically avoided in pregnancy because it crosses the placenta and can cause fetal complications, especially if used in the first trimester or near term.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Apixaban</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Apixaban, a newer oral anticoagulant, is generally avoided in pregnancy due to a lack of sufficient data supporting its safety for the fetus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fondaparinux</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Although Fondaparinux has a lower risk of heparin-induced thrombocytopenia (HIT), it is not the first-line choice during pregnancy. The data on its safety in pregnancy are limited, and therefore, LMWH is preferred.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low Molecular Weight Heparin (LMWH) is the preferred anticoagulant for both the treatment and prophylaxis of DVT during pregnancy across all trimesters due to its safety profile for both the mother and fetus.</span></span></span></p>",
      "correct_choice_id": 228542,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7091,
      "choices": [
        {
          "id": 28332,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hydralazine - heart failure</span></span></span></p>"
        },
        {
          "id": 28333,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Atenolol - hemolytic anemia</span></span></span></p>"
        },
        {
          "id": 28334,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Aliskiren - hypokalemia</span></span></span></p>"
        },
        {
          "id": 28335,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Verapamil &ndash; constipation</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the correct match, regarding the drug and its adverse effect?</span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q8115689",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999936,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Verapamil &ndash; constipation</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct match regarding the drug and its adverse effect (read carefully, they have not asked the indication) is verapamil causes constipation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil is a Non DHP calcium channel blocker. It can cause constipation as its side effect.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Hydralazine is a vasodilator which can cause drug-induced lupus. It does not cause heart failure as an adverse effect, rather It is used in treatment of heart failure.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Atenolol is a cardio selective beta blocker. Bradycardia can be seen as a side effect, not hemolytic anemia. Hemolytic anemia is a side effect of methyl dopa.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Aliskiren is a direct renin inhibitor. The side effect of aliskiren is hyperkalemia and not hypokalemia.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Verapamil, a non-dihydropyridine calcium channel blocker, is associated with constipation as a common adverse effect. Other drugs and their incorrect matches in this context include hydralazine (which can cause drug-induced lupus), atenolol (which does not cause hemolytic anemia), and aliskiren (which can cause hyperkalemia, not hypokalemia).</span></span></span></p>",
      "correct_choice_id": 28335,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33853,
      "choices": [
        {
          "id": 135250,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">IUCD</span></p>"
        },
        {
          "id": 135251,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">OCP</span></p>"
        },
        {
          "id": 135252,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Levonorgestrel</span></p>"
        },
        {
          "id": 135253,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A female had unprotected sexual intercourse and now more than 5 days have passed. She fears getting pregnant. What is the contraceptive of choice in this case?</span> <span style=\"font-size:12.0pt;\">(Fmge Jan 2024)</span></p>",
      "unique_key": "Q9806944",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999940,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. A) IUCD</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The only option suitable for emergency contraception in this scenario (more than 5 days after unprotected intercourse) is the IUCD, specifically the copper IUCD. It can be inserted up to five days after unprotected intercourse and is highly effective in preventing pregnancy. The other options, OCP and Levonorgestrel, are typically used within a shorter time frame after unprotected sex and would not be the best choices in this situation.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. OCP (Oral Contraceptive Pills):</strong> These are typically used as a regular method of contraception and are not suitable for emergency contraception if more than 72 hours have passed since unprotected intercourse.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Levonorgestrel:</strong> This is a form of emergency contraceptive pill. It is most effective when taken within 72 hours (3 days) after unprotected sex and its effectiveness decreases significantly after this period.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. None of the above:</strong> This option would be chosen if none of the other options were appropriate.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>IUCD (Intrauterine Contraceptive Device)&nbsp;</strong>is an effective form of emergency contraception. Certain types of IUCDs, particularly the copper IUCD, can be used as emergency contraception if inserted within five days (120 hours) after unprotected intercourse. They are one of the most effective forms of emergency contraception available.</span></p>",
      "correct_choice_id": 135250,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65031,
      "choices": [
        {
          "id": 259301,
          "text": "<p><span style=\"font-size:12.0pt;\">Midazolam</span></p>"
        },
        {
          "id": 259302,
          "text": "<p><span style=\"font-size:12.0pt;\">Ketamine</span></p>"
        },
        {
          "id": 259303,
          "text": "<p><span style=\"font-size:12.0pt;\">Propofol</span></p>"
        },
        {
          "id": 259304,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiopentone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs has NMDA receptor antagonist activity and is also used as a bronchodilator? (Twisted PYQ)</span></p>",
      "unique_key": "Q3639506",
      "question_audio": null,
      "question_video": null,
      "map_id": 15323668,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Ketamine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Ketamine is a well-known NMDA receptor antagonist that blocks the action of glutamate, an excitatory neurotransmitter, at the NMDA receptor. This mechanism underlies its unique dissociative anesthetic effects, potent analgesia, and other applications. Additionally, ketamine is an excellent bronchodilator, making it useful in conditions like severe asthma where airway relaxation is critical.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Midazolam:</strong> Midazolam enhances the activity of GABA, an inhibitory neurotransmitter, and does not act on NMDA receptors or function as a bronchodilator.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Propofol:</strong> Propofol primarily enhances GABAergic transmission and has no significant effect on NMDA receptors or bronchodilation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Thiopentone:</strong> Thiopentone, a barbiturate, also acts via GABAergic mechanisms and does not antagonize NMDA receptors or serve as a bronchodilator.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Ketamine is a unique NMDA receptor antagonist with significant clinical applications, including dissociative anesthesia, potent analgesia, and bronchodilation. These properties make it particularly useful in pediatric anesthesia and in patients with respiratory conditions like asthma.</span></p>",
      "correct_choice_id": 259302,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23220,
      "choices": [
        {
          "id": 92844,
          "text": "<p><span style=\"font-size:12pt;\">Vaginal candidiasis</span></p>"
        },
        {
          "id": 92845,
          "text": "<p><span style=\"font-size:12pt;\">Increased normal vaginal discharge</span></p>"
        },
        {
          "id": 92846,
          "text": "<p><span style=\"font-size:12pt;\">Bacterial vaginosis</span></p>"
        },
        {
          "id": 92847,
          "text": "<p><span style=\"font-size:12pt;\">Chlamydia infection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A woman who is using oral contraceptive pills (OCPs) experiences white vaginal discharge without itching or a foul odor. The discharge causes yellow staining on her underwear. Upon examination, the discharge reveals the presence of typical lactobacilli and an acidic pH. What is the most likely diagnosis in this case?&nbsp;</span>(INICET MAY 2023)</p>",
      "unique_key": "Q8162193",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999773,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Increased normal vaginal discharge</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The given clinical scenario suggests a diagnosis of Leucorrhea (Increased vaginal discharge).&nbsp;Leucorrhea presents with excessive whitish, yellowish, or greenish vaginal discharge. It is non-irritant, no purulent and non-offensive.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Vaginal candidiasis</strong>: Vaginal candidiasis presents with itching and a white thick, curdy discharge.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Bacterial vaginosis</strong>: Bacterial vaginosis is characterized by a thin, gray, foul-smelling discharge.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Chlamydia infection</strong>: Chlamydia infection can by asymptomatic or present with discharge but is not associated with yellow discharge.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Increased normal vaginal discharge, known as leucorrhea, can occur in women using oral contraceptive pills. This discharge is typically white or yellow, non-irritant, no purulent, no offensive, and associated with the presence of lactobacilli and an acidic pH.</span></p>",
      "correct_choice_id": 92845,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7045,
      "choices": [
        {
          "id": 28148,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
        },
        {
          "id": 28149,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Saxagliptin</span></span></span></p>"
        },
        {
          "id": 28150,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
        },
        {
          "id": 28151,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs does not need dose adjustment in renal failure? (</span></span>INICET May 2020)</p>",
      "unique_key": "Q1530757",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999964,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes. Unlike other DPP-4 inhibitors, linagliptin is primarily excreted via the enterohepatic system, with only a small fraction eliminated by the kidneys. Therefore, it does not require dose adjustments in patients with renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sitagliptin:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This DPP-4 inhibitor is primarily excreted by the kidneys, and its dose usually needs to be adjusted in patients with renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Saxagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Saxagliptin and its active metabolite are primarily eliminated by the kidneys, necessitating dose adjustments in patients with renal failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vildagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Vildagliptin is partially excreted by the kidneys, and dose adjustment is recommended in patients with moderate to severe renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin is a unique DPP-4 inhibitor that does not require dose adjustments in patients with renal failure due to its primary excretion via the enterohepatic system. This makes it an advantageous option for managing type 2 diabetes in patients with compromised renal function.</span></span></span></p>",
      "correct_choice_id": 28151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3882,
      "choices": [
        {
          "id": 15507,
          "text": "<p><span style=\"font-size:12.0pt;\">Poxvirus</span></p>"
        },
        {
          "id": 15508,
          "text": "<p><span style=\"font-size:12.0pt;\">Ebstein barr virus</span></p>"
        },
        {
          "id": 15509,
          "text": "<p><span style=\"font-size:12.0pt;\">Adenovirus</span></p>"
        },
        {
          "id": 15510,
          "text": "<p><span style=\"font-size:12.0pt;\">Parvovirus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following causes aplastic crisis in hereditary spherocytosis?</span> <span style=\"font-size:12.0pt;\">(INICET MAY 2021)</span></p>",
      "unique_key": "Q5477769",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999944,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Parvovirus</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>ParvoVirus-B19 infects erythroid progenitor cells and inhibits erythropoiesis</strong>, leading to acute erythroblastopenia and reticulocytopenia. The bone marrow in patients with transient aplastic crisis is characterized by an absence of maturing erythroid precursors and presence of giant pro-normoblasts. Although <u>giant pro-normoblasts are suggestive of parvovirus B19 infection, they are not diagnostic of the disease</u>. Aplastic crisis in a patient with hereditary spherocytosis is because of pancytopenia accompanied with a marked decrease in reticulocytes. <strong>Bone marrow aspiration may not be routinely required when viral infection-induced aplastic crisis is highly suspected.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Poxvirus</strong>: Poxviruses are not associated with causing aplastic crisis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Epstein-Barr virus</strong>: While Epstein-Barr virus (EBV) can cause hematologic abnormalities, it is not typically associated with causing aplastic crisis in hereditary spherocytosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Adenovirus</strong>: Adenovirus infections are common but are not known to cause aplastic crisis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Parvovirus B19 is the causative agent for aplastic crisis in patients with hereditary spherocytosis. It infects erythroid progenitor cells, inhibiting erythropoiesis and leading to a significant decrease in reticulocytes, causing acute erythroblastopenia.</span></p>",
      "correct_choice_id": 15510,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6463,
      "choices": [
        {
          "id": 25821,
          "text": "<p><span style=\"font-size:12.0pt;\">Highly bound to plasma proteins</span></p>"
        },
        {
          "id": 25822,
          "text": "<p><span style=\"font-size:12.0pt;\">Confined to vascular compartment</span></p>"
        },
        {
          "id": 25823,
          "text": "<p><span style=\"font-size:12.0pt;\">Sequestered in body tissues</span></p>"
        },
        {
          "id": 25824,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and B</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Apparent volume of distribution of a drug is very high (6L/kg). Which of the following is true regarding the distribution of that drug? (NEET PG 2019)</span></p>",
      "unique_key": "Q7391971",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999775,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Sequestered in body tissues</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">A Vd (volume of distribution) of 6 L/kg means approx. 420 L (6 x 70) in a 70 Kg person. It is much higher than blood volume of 5L.</span></li><li><span style=\"font-size:12.0pt;\">A high Vd suggests that the drug is extensively distributed beyond the blood and into the tissues. This often implies that the drug has a high affinity for tissues, effectively getting \"sequestered\" or stored there.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Highly bound to plasma proteins</strong>: A drug that is highly bound to plasma proteins would typically have a lower Vd because it is mostly confined to the bloodstream. Plasma protein binding keeps the drug within the vascular space, preventing its distribution into tissues.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Confined to vascular compartment</strong>: A low Vd would suggest that the drug is primarily in the vascular compartment, including plasma and blood cells. A high Vd of 6L/kg indicates the opposite, suggesting that the drug is widely distributed in tissues rather than confined to the vascular compartment.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Therefore, a high Vd suggests that the drug is stored or sequestered in various body tissues, making option C the correct answer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A high volume of distribution (Vd) suggests that the drug is widely distributed throughout the body and sequestered in various tissues, rather than being confined to the bloodstream or vascular compartment.</span></p>",
      "correct_choice_id": 25823,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6413,
      "choices": [
        {
          "id": 25621,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium channel blockers</span></p>"
        },
        {
          "id": 25622,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta blockers</span></p>"
        },
        {
          "id": 25623,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitrates</span></p>"
        },
        {
          "id": 25624,
          "text": "<p><span style=\"font-size:12.0pt;\">ACE inhibitors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient on angina medication comes to you with erectile dysfunction. Because the patient is being treated with one drug, you decide against prescribing sildenafil, that drug is?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p>",
      "unique_key": "Q6803996",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999948,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Nitrates</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Nitrates and Sildenafil should not be prescribed together. Sildenafil is a PDE-5 inhibitor that is useful in the treatment of erectile dysfunction. Nitrates are metabolized into NO, that stimulates Guanylate cyclase and increases the level of cGMP and causes vasodilation. For the metabolism of cGMP, Phosphodiesterase enzyme will be needed, and if that is inhibited, then it will lead to severe hypotension due to the potentiation of action of nitrates.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Calcium channel blockers:&nbsp;</strong>Calcium channel blockers are used to treat hypertension and angina. They work by relaxing the blood vessels and reducing the heart's workload. They do not interact dangerously with sildenafil.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Beta blockers:&nbsp;</strong>Beta blockers are also used to treat hypertension, angina, and other cardiovascular conditions. They reduce the heart rate and the force of contraction, thus reducing the heart's oxygen demand. They do not have a dangerous interaction with sildenafil.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. ACE inhibitors:&nbsp;</strong>ACE inhibitors are used to treat hypertension and heart failure by relaxing blood vessels. They work by inhibiting the angiotensin-converting enzyme, reducing the production of angiotensin II. ACE inhibitors do not have a dangerous interaction with sildenafil.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Nitrates and sildenafil should not be used together due to the risk of severe hypotension from the combined effect on cGMP levels leading to excessive vasodilation.</span></p>",
      "correct_choice_id": 25623,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "OlderNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7040,
      "choices": [
        {
          "id": 28128,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></p>"
        },
        {
          "id": 28129,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sertaconazole</span></span></span></p>"
        },
        {
          "id": 28130,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luliconazole</span></span></span></p>"
        },
        {
          "id": 28131,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Terbinafine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following topical antifungal has both anti- inflammatory effects and anti-pruritic action? (</span></span>INICET May 2020)</p>",
      "unique_key": "Q2572608",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999947,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Sertaconazole</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sertaconazole has both anti-inflammatory effects and anti-pruritic action. It is used to treat dermatophytosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></strong> <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole:&nbsp;</span></strong>Ketoconazole is a broad-spectrum antifungal that also has anti-androgenic effects. However, it does not possess notable anti-inflammatory or anti-pruritic properties.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></strong> <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luliconazole:&nbsp;</span></strong>Luliconazole is effective against dermatophytes and yeasts, but it does not have significant anti-inflammatory or anti-pruritic actions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></strong> <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Terbinafine:&nbsp;</span></strong>Terbinafine is mainly used to treat dermatophytosis. It does not have substantial anti-inflammatory or anti-pruritic effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/18/screenshot-2024-07-18-101732.png\" style=\"height:681px; width:1000px\" /></p>",
      "correct_choice_id": 28129,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24715,
      "choices": [
        {
          "id": 98821,
          "text": "<p><span style=\"font-size:12.0pt;\">Voglibose</span></p>"
        },
        {
          "id": 98822,
          "text": "<p><span style=\"font-size:12.0pt;\">Alogliptin</span></p>"
        },
        {
          "id": 98823,
          "text": "<p><span style=\"font-size:12.0pt;\">Pramlintide</span></p>"
        },
        {
          "id": 98824,
          "text": "<p><span style=\"font-size:12.0pt;\">Liraglutide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old female with diabetes mellitus has experienced a decrease in her HbA1c levels from 7.6 to 6.7 after starting a new oral medication. Laboratory tests show that she has high levels of GIP and GLP-1 and low levels of glucagon. Which of the following oral drugs was most likely administered to this patient?&nbsp;</span>(INICET MAY 2023)</p>",
      "unique_key": "Q2702561",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999949,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Alogliptin.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Alogliptin is a DPP-4 inhibitor, an oral class of drugs used in the treatment of diabetes. DPP-4 inhibitors work by preventing the breakdown of GLP-1, thereby increasing the levels of GLP-1 in the body, which in turn enhances insulin secretion, reduces glucagon secretion, and slows gastric emptying.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Voglibose</strong>: Voglibose is an alpha-glucosidase inhibitor that delays the absorption of carbohydrates in the intestines. It does not directly affect the levels of incretin hormones like GLP-1 and GIP, nor does it significantly influence glucagon levels.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Pramlintide</strong>: Pramlintide is an amylin analogue that is used to help control blood sugar levels. It is typically administered by injection and does not significantly increase GLP-1 or GIP levels. It works by slowing gastric emptying and suppressing glucagon secretion, but it does not match the profile described in the question as closely as alogliptin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Liraglutide</strong>: Liraglutide is a GLP-1 agonist, which would indeed lead to increased GLP-1 levels and decreased glucagon levels. However, liraglutide is administered by injection and not orally. This makes it less likely to be the medication described in the scenario, which specifies an oral drug.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Alogliptin, a DPP-4 inhibitor, is the most likely drug responsible for the increase in GLP-1 and GIP levels and the decrease in glucagon levels in this patient. It effectively lowers HbA1c levels and is administered orally, fitting the description provided.</span></p>",
      "correct_choice_id": 98822,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65027,
      "choices": [
        {
          "id": 259285,
          "text": "<p><span style=\"font-size:12.0pt;\">G protein-coupled receptor</span></p>"
        },
        {
          "id": 259286,
          "text": "<p><span style=\"font-size:12.0pt;\">Transmembrane receptor linked to tyrosine kinase</span></p>"
        },
        {
          "id": 259287,
          "text": "<p><span style=\"font-size:12.0pt;\">Nuclear receptor</span></p>"
        },
        {
          "id": 259288,
          "text": "<p><span style=\"font-size:12.0pt;\">Ion channel receptor</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D exerts its effects by binding to which of the following classes of receptors? (Twisted PYQ)</span></p>",
      "unique_key": "Q7363144",
      "question_audio": null,
      "question_video": null,
      "map_id": 15323664,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Nuclear receptor</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Vitamin D binds to the <strong>Vitamin D Receptor (VDR)</strong>, which is a member of the nuclear receptor superfamily. Like thyroid hormone receptors, VDRs are intracellular and primarily located in the nucleus. Upon binding to active Vitamin D (calcitriol), the VDR forms a complex with the retinoid X receptor (RXR) and attaches to specific DNA sequences, regulating gene transcription. This process is vital for calcium homeostasis and bone metabolism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A: G protein-coupled receptor</strong> – GPCRs are involved in fast signal transduction and are not relevant to Vitamin D's mechanism of action.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B: Transmembrane receptor linked to tyrosine kinase</strong> – These receptors, such as the insulin receptor, mediate signaling through tyrosine phosphorylation cascades and are not involved in Vitamin D signaling.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D: Ion channel receptor</strong> – These ligand-gated ion channels facilitate rapid ion flow in response to ligand binding, unrelated to Vitamin D's genomic actions.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Vitamin D, like thyroid hormone, acts through <strong>nuclear receptors</strong>, emphasizing the importance of transcriptional regulation in maintaining physiological processes like calcium homeostasis and skeletal health.</span></p>",
      "correct_choice_id": 259287,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44783,
      "choices": [
        {
          "id": 178779,
          "text": "<p><span style=\"font-size:16px;\">Osteonecrosis of jaw bone</span></p>"
        },
        {
          "id": 178780,
          "text": "<p><span style=\"font-size:16px;\">Osteosarcoma</span></p>"
        },
        {
          "id": 178781,
          "text": "<p><span style=\"font-size:16px;\">Subtrochanteric fracture</span></p>"
        },
        {
          "id": 178782,
          "text": "<p><span style=\"font-size:16px;\">Loss of bone mass</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following is an adverse effect with the long-term use of intermittent teriparatide for treatment of osteoporosis?</span></p>",
      "unique_key": "Q9508508",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056333,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Osteosarcoma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Osteosarcoma is a rare but serious potential adverse effect associated with the long-term use of teriparatide. This risk was identified in animal studies where high doses of teriparatide caused osteosarcoma in rats. Although this effect has not been conclusively demonstrated in humans, the potential risk has led to caution in prescribing teriparatide for long durations, usually limited to a maximum of 2 years of use.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option</strong>&nbsp;<strong>A.</strong>&nbsp;<strong>Osteonecrosis of the jaw bone</strong>:&nbsp;Osteonecrosis of the jaw is more commonly associated with bisphosphonates and denosumab, not with teriparatide. Teriparatide, being a parathyroid hormone analog, does not typically cause this condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option</strong>&nbsp;<strong>C.</strong>&nbsp;<strong>Subtrochanteric fracture</strong>:&nbsp;Subtrochanteric fractures are more commonly associated with long-term use of bisphosphonates rather than teriparatide. Teriparatide, by stimulating new bone formation, is less likely to cause these types of fractures.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option</strong>&nbsp;<strong>D.</strong>&nbsp;<strong>Loss of bone mass</strong>:&nbsp;Teriparatide is used to increase bone mass and strength by stimulating bone formation. Loss of bone mass is not a recognized adverse effect of teriparatide; rather, the medication is prescribed to counteract this condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">In summary, the most significant potential adverse effect associated with the long-term use of teriparatide is the development of osteosarcoma, albeit this risk is based primarily on animal studies. Therefore, clinicians are advised to limit the duration of teriparatide therapy and monitor patients closely.</span></p>",
      "correct_choice_id": 178780,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20918,
      "choices": [
        {
          "id": 83636,
          "text": "<p><span style=\"font-size:12.0pt;\">Atropine toxicity</span></p>"
        },
        {
          "id": 83637,
          "text": "<p><span style=\"font-size:12.0pt;\">Side effect of pralidoxime</span></p>"
        },
        {
          "id": 83638,
          "text": "<p><span style=\"font-size:12.0pt;\">Due to organophosphate poisoning</span></p>"
        },
        {
          "id": 83639,
          "text": "<p><span style=\"font-size:12.0pt;\">Idiopathic</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient comes to the casualty with organophosphate poisoning. He was started on atropine infusion and pralidoxime. After 2 hours, the patient had a sudden rise in temperature. What is the likely cause of fever? (NEET PG 2023)</span></p>",
      "unique_key": "Q1989425",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999946,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Atropine toxicity</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The most likely cause of fever in this patient is atropine toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The clinical scenario is of organophosphate poisoning and patient was started on atropine infusion and pralidoxime.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Atropine is a non-specific muscarinic receptor blocker, but not the nicotinic effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A/E of Atropine include –</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">↑body temperature (due to ↓sweating)</span></li><li><span style=\"font-size:12.0pt;\">↑ HR</span></li><li><span style=\"font-size:12.0pt;\">Dry mouth, Dry &amp; flushed skin</span></li><li><span style=\"font-size:12.0pt;\">Cycloplegia</span></li><li><span style=\"font-size:12.0pt;\">Constipation</span></li><li><span style=\"font-size:12.0pt;\">Disorientation</span></li><li><span style=\"font-size:12.0pt;\">Can cause acute angle-closure glaucoma in older adults (due to mydriasis)</span></li><li><span style=\"font-size:12.0pt;\">Urinary retention in men with prostatic hyperplasia</span></li><li><span style=\"font-size:12.0pt;\">Hyperthermia in infants</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pralidoxime is given as an adjuvant to atropine in cases of organophosphate poisoning. It&nbsp;does not increase body temperature.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Hence, the sudden rise in body temperature is most likely attributed to Atropine Toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Side effect of pralidoxime: </strong>Pralidoxime is used as an adjuvant in the treatment of organophosphate poisoning to reactivate acetylcholinesterase. It does not typically cause hyperthermia or significantly affect body temperature.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Due to organophosphate poisoning:&nbsp;</strong>Organophosphate poisoning typically causes symptoms due to excessive acetylcholine, such as sweating, salivation, bronchorrhea, bradycardia, and muscle fasciculations. It does not typically cause a sudden rise in temperature as described in this scenario.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Idiopathic:&nbsp;</strong>An idiopathic cause is one that arises spontaneously or for which the cause is unknown. Given the context of the medication administration and known side effects, the fever is more likely due to atropine toxicity rather than an unexplained cause.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/10/picture5.jpg\" alt=\"\" width=\"602\" height=\"488\"></span></p>",
      "correct_choice_id": 83636,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5504,
      "choices": [
        {
          "id": 21988,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Granisetron, Dexamethasone and Aprepitant </span></span></span></p>"
        },
        {
          "id": 21989,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Metoclopramide, dexamethasone and domperidone </span></span></span></p>"
        },
        {
          "id": 21990,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Prochlorperazine, Granisetron and domperidone </span></span></span></p>"
        },
        {
          "id": 21991,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Promethazine, doxylamine and metoclopramide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is receiving chemotherapy with platinum compounds. Which of the following drugs are used for treatment of chemotherapy induced nausea and vomiting? (Fmge Jan 2023)</span></span></p>",
      "unique_key": "Q9844761",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056324,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Granisetron, Dexamethasone and Aprepitant</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Granisetron + Dexamethasone + Aprepitant is used to treat Chemotherapy-induced Nausea and Vomiting.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Granisetron is a 5-HT3 Receptor blocker (others being Ondansetron, Palonosetron etc.).</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Aprepitant is NK1 /Neurokinin antagonist.</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">5-HT3 blockers are in general the DOC for Chemotherapy induced vomiting, Radiotherapy induced vomiting and post operative vomiting.</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Neurokinin or the substance P antagonists are the DOC for delayed vomiting by Cisplatin.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Metoclopramide, Dexamethasone and Domperidone:</span></strong><span style=\"font-size:12.0pt\"> While metoclopramide and domperidone are antiemetics, they are less effective for CINV compared to 5-HT3 antagonists and NK1 antagonists. Dexamethasone is appropriate, but the combination lacks the efficacy of the preferred regimen.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Prochlorperazine, Granisetron and Domperidone:</span></strong><span style=\"font-size:12.0pt\"> Prochlorperazine is an antipsychotic with antiemetic properties but is not as effective for CINV as NK1 antagonists. Granisetron is appropriate, but the combination lacks the efficacy of aprepitant.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Promethazine, Doxylamine and Metoclopramide:</span></strong><span style=\"font-size:12.0pt\"> Promethazine and doxylamine are antihistamines and are less effective for CINV. Metoclopramide is also less effective compared to the preferred agents.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For the treatment of chemotherapy-induced nausea and vomiting, particularly with platinum compounds like cisplatin, the combination of Granisetron (a 5-HT3 receptor antagonist), Dexamethasone (a corticosteroid), and Aprepitant (an NK1 receptor antagonist) is highly effective. This regimen targets multiple pathways involved in emesis and provides comprehensive control of both acute and delayed phases of CINV.</span></span></p>",
      "correct_choice_id": 21988,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65030,
      "choices": [
        {
          "id": 259297,
          "text": "<p><span style=\"font-size:12.0pt;\">Ketamine</span></p>"
        },
        {
          "id": 259298,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiopentone</span></p>"
        },
        {
          "id": 259299,
          "text": "<p><span style=\"font-size:12.0pt;\">Propofol</span></p>"
        },
        {
          "id": 259300,
          "text": "<p><span style=\"font-size:12.0pt;\">Etomidate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is preferred for total intravenous anaesthesia in a hemodynamically unstable patient? (Twisted PYQ)</span></p>",
      "unique_key": "Q9223564",
      "question_audio": null,
      "question_video": null,
      "map_id": 15323667,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Etomidate</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Etomidate is the preferred drug for induction in hemodynamically unstable patients due to its minimal impact on the cardiovascular system. It maintains hemodynamic stability by preserving cardiac output and blood pressure. These properties make it a suitable choice for total intravenous anesthesia in patients at risk of cardiovascular collapse.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Ketamine:</strong> Ketamine also preserves cardiovascular stability but is more commonly used in trauma or emergency situations where dissociative anesthesia is beneficial. It is not typically the first choice for TIVA in controlled surgical settings.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Thiopentone:</strong> Thiopentone is associated with significant cardiovascular depression and is not ideal for hemodynamically unstable patients.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Propofol:</strong> While propofol is the standard for TIVA due to its rapid onset and offset, it can cause significant hypotension and is not ideal for patients with cardiovascular instability.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Etomidate is the agent of choice for total intravenous anesthesia in hemodynamically unstable patients due to its cardiovascular stability. For stable patients, propofol remains the preferred agent for TIVA due to its favorable pharmacokinetics and side effect profile.</span></p>",
      "correct_choice_id": 259300,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6875,
      "choices": [
        {
          "id": 27468,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hyperprolactinemia</span></span></span></p>"
        },
        {
          "id": 27469,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PCOD</span></span></span></p>"
        },
        {
          "id": 27470,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypogonadotrophic hypogonadism</span></span></span></p>"
        },
        {
          "id": 27471,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PID</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 27-year-old female came for treatment of infertility to OPD, Bromocriptine was prescribed. What could be the possible reason? (AIIMS NOV 2017)</span></span></p>",
      "unique_key": "Q9960925",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999774,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Hyperprolactinemia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bromocriptine is a dopamine agonist that acts on D2 receptors. It is effective in reducing prolactin secretion, which is useful in treating hyperprolactinemia. Elevated levels of prolactin can inhibit the secretion of gonadotropin-releasing hormone (GnRH), leading to decreased levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which can cause anovulation and infertility.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mechanism of Bromocriptine:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Action:</span></strong><span style=\"font-size:12.0pt\"> Bromocriptine stimulates D2 dopamine receptors.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Effect:</span></strong><span style=\"font-size:12.0pt\"> Decreases prolactin secretion from the pituitary gland.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Result:</span></strong><span style=\"font-size:12.0pt\"> Reduction in prolactin levels can restore normal GnRH secretion, normalizing FSH and LH levels and resuming ovulatory cycles, thus addressing infertility.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PCOD (Polycystic Ovarian Disease):&nbsp;</span></strong><span style=\"font-size:12.0pt\">PCOD is characterized by multiple cysts in the ovaries, insulin resistance, and hyperandrogenism. Treatment usually involves lifestyle changes, metformin, or hormonal therapies, not specifically bromocriptine unless associated with hyperprolactinemia.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypogonadotrophic hypogonadism:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This condition involves low levels of FSH and LH due to hypothalamic or pituitary dysfunction. Treatment often includes gonadotropins or pulsatile GnRH therapy. Bromocriptine is not indicated unless hyperprolactinemia is a contributing factor.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PID (Pelvic Inflammatory Disease):&nbsp;</span></strong><span style=\"font-size:12.0pt\">PID is an infection of the female reproductive organs. Treatment typically involves antibiotics. Bromocriptine has no role in treating PID.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bromocriptine is a Dopaminergic agonist that leads to a decrease in the secretion of Prolactin by its action on the D2 dopaminergic receptors of the Nigrostriatal Pathway. Hyperprolactinemia can cause infertility by inhibiting the release of GnRH from the hypothalamus, leading to a decrease in the levels of FSH and LH.</span></span></span></p>",
      "correct_choice_id": 27468,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57292,
      "choices": [
        {
          "id": 228545,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epsilon Amino Caproic acid</span></span></p>"
        },
        {
          "id": 228546,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel</span></span></p>"
        },
        {
          "id": 228547,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tenecteplase</span></span></p>"
        },
        {
          "id": 228548,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspirin</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is represented in the below figure by drug X? (NEET PG 2024)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/16/screenshot-2024-09-16-181944.jpg\" style=\"height:353px; width:400px\" /></span></span></span></p>",
      "unique_key": "Q5453364",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056335,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Epsilon Amino Caproic acid</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The diagram illustrates the process of fibrinolysis, where plasminogen is converted into plasmin by activators like streptokinase. Plasmin is responsible for breaking down fibrin into fibrin degradation products, effectively dissolving clots. Drug X, as represented in the diagram, inhibits this process, thereby acting as an anti-fibrinolytic agent. Epsilon Amino Caproic Acid (EACA) is an anti-fibrinolytic drug that works by inhibiting the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin and stabilizing clots.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Clopidogrel</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is an antiplatelet drug that prevents blood clots by inhibiting platelet aggregation. It does not have any direct role in inhibiting fibrinolysis as shown in the diagram.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tenecteplase</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a thrombolytic agent that promotes the conversion of plasminogen to plasmin, thereby enhancing fibrinolysis and breaking down clots. It is the opposite of what Drug X does in the diagram.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Aspirin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is an antiplatelet drug that inhibits the cyclooxygenase enzyme, reducing the formation of thromboxane A2, which is involved in platelet aggregation. Like Clopidogrel, it does not inhibit fibrinolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epsilon Amino Caproic Acid (EACA) is an anti-fibrinolytic drug that inhibits the activation of plasminogen, thereby preventing the breakdown of fibrin and stabilizing blood clots.</span></span></span></p>",
      "correct_choice_id": 228545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44860,
      "choices": [
        {
          "id": 179087,
          "text": "<p><span style=\"font-size:16px;\">1, 2 and 3</span></p>"
        },
        {
          "id": 179088,
          "text": "<p><span style=\"font-size:16px;\">1 and 3</span></p>"
        },
        {
          "id": 179089,
          "text": "<p><span style=\"font-size:16px;\">2, 3 and 4</span></p>"
        },
        {
          "id": 179090,
          "text": "<p><span style=\"font-size:16px;\">1, 2, 3 and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following is a suicide inhibitor?&nbsp; (INICET May 2024)</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:16px;\">Nor-ethindrone</span></li><li><span style=\"font-size:16px;\">Ritonavir</span></li><li><span style=\"font-size:16px;\">Spironolactone</span></li><li><span style=\"font-size:16px;\">Benzbromarone</span></li></ol>",
      "unique_key": "Q2983402",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056325,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. A) 1, 2 and 3</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">A&nbsp;suicide inhibitor&nbsp;(also known as a mechanism-based inhibitor) is a type of enzyme inhibitor that binds to an enzyme and undergoes a catalytic reaction, leading to the formation of an irreversible complex. During this reaction, the inhibitor is converted into a reactive form by the enzyme itself, which then covalently binds to the enzyme, permanently inactivating it.&nbsp;In essence, the enzyme “commits suicide” by converting the inhibitor into a form that irreversibly binds to it, thereby blocking the enzyme's activity permanently.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Among the given options, nor-ethindrone, ritonavir and spironolactone are suicide inhibitors whereas benzbromarone is not.&nbsp;</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:16px;\"><strong>Nor-ethindrone</strong>: Nor-ethindrone is a synthetic progestin that is commonly used in hormonal contraceptives. It is also classified as a&nbsp;<strong>suicide inhibitor</strong>&nbsp;due to its irreversible binding to its target enzyme, leading to permanent inhibition of enzyme activity.</span></li><li><span style=\"font-size:16px;\"><strong>Ritonavir</strong>: Ritonavir is an HIV protease inhibitor that acts as a&nbsp;<strong>suicide inhibitor</strong>. It binds irreversibly to the HIV protease enzyme, permanently inactivating it.</span></li><li><span style=\"font-size:16px;\"><strong>Spironolactone</strong>: Spironolactone is a potassium-sparing diuretic and aldosterone antagonist. It is also categorized as a&nbsp;<strong>suicide inhibitor</strong>&nbsp;because it irreversibly inhibits the 17α-hydroxylase enzyme involved in steroid synthesis.</span></li><li><span style=\"font-size:16px;\"><strong>Benzbromarone:&nbsp;</strong>Benzbromarone is a uricosuric drug used to treat gout by increasing the renal excretion of uric acid. However, it is not classified as a suicide inhibitor. While it has therapeutic uses, it does not act by irreversibly inactivating enzymes like suicide inhibitors do.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Suicide inhibitors, also known as mechanism-based inhibitors, irreversibly bind to and permanently inactivate their target enzymes. This type of inhibition is significant because the enzyme activity cannot be restored unless new enzymes are synthesized by the body.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Mnemonic to Remember Important Suicide Inhibitors:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>“Every Nurse Sees The Clot Results Promptly”</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:16px;\"><strong>E</strong>: Ethinyl estradiol</span></li><li><span style=\"font-size:16px;\"><strong>N</strong>: Norethindrone</span></li><li><span style=\"font-size:16px;\"><strong>S</strong>: Spironolactone</span></li><li><span style=\"font-size:16px;\"><strong>T</strong>: Ticlopidine</span></li><li><span style=\"font-size:16px;\"><strong>C</strong>: Clopidogrel</span></li><li><span style=\"font-size:16px;\"><strong>R</strong>: Ritonavir</span></li><li><span style=\"font-size:16px;\"><strong>P</strong>: Propylthiouracil</span></li></ul>",
      "correct_choice_id": 179087,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33852,
      "choices": [
        {
          "id": 135246,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Vitamin C</span></p>"
        },
        {
          "id": 135247,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Tea</span></p>"
        },
        {
          "id": 135248,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Sprouts</span></p>"
        },
        {
          "id": 135249,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Gastric acid</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following factors can decrease iron absorption?</span> <span style=\"font-size:12.0pt;\">(Fmge Jan 2024)</span></p>",
      "unique_key": "Q9038833",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999767,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Tea</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Tea, especially black tea, contains compounds called tannins. Tannins can bind to iron, making it harder for the body to absorb. Therefore, drinking tea, especially with meals, can decrease the absorption of iron.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Vitamin C:</strong> Vitamin C, also known as ascorbic acid, actually enhances iron absorption, especially non-heme iron (the form of iron found in plant-based foods). It does this by converting iron into a form that is more easily absorbed by the body.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Sprouts:</strong> Sprouts, like other plant-based foods, contain phytates (phytic acid), which can bind to minerals like iron and inhibit their absorption. However, the process of sprouting reduces the phytate content, which may actually improve the availability of iron.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Gastric Acid:</strong> Gastric acid is crucial for iron absorption as it helps convert iron into its ferrous (Fe2+) form, which is more easily absorbed. Reduced gastric acid can lead to decreased iron absorption, as seen in conditions like atrophic gastritis or with the use of certain medications (like proton pump inhibitors).</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Tea, particularly due to its tannin content, is known to decrease iron absorption. The other options, Vitamin C and gastric acid, typically aid in iron absorption, while sprouts, although containing phytates, have reduced phytate levels due to the sprouting process and are not the primary dietary concern for iron absorption inhibition</span></p>",
      "correct_choice_id": 135247,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6521,
      "choices": [
        {
          "id": 26053,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        },
        {
          "id": 26054,
          "text": "<p><span style=\"font-size:12.0pt;\">Methysergide</span></p>"
        },
        {
          "id": 26055,
          "text": "<p><span style=\"font-size:12.0pt;\">Bleomycin</span></p>"
        },
        {
          "id": 26056,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitrofurantoin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is not likely to cause a pleural pathology? (NEET PG 2022)</span></p>",
      "unique_key": "Q9157054",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056327,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Metformin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Metformin is an oral hypoglycemic agent used primarily in the treatment of type 2 diabetes mellitus. It works by decreasing hepatic glucose production and increasing insulin sensitivity. Metformin is not associated with pleural pathologies, making it the correct choice in this context.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Methysergide</strong>: Methysergide is a medication used to prevent migraine headaches and is known for its potential to cause retroperitoneal and pleural fibrosis. This pleural pathology is a serious adverse effect, although the drug is not commonly used today due to this risk.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Bleomycin</strong>: Bleomycin is a chemotherapeutic agent used in the treatment of various cancers. One of its well-known side effects is pulmonary toxicity, which can manifest as pulmonary fibrosis. Pleural involvement, including pleural effusions and fibrosis, can occur secondary to its pulmonary effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Nitrofurantoin</strong>: Nitrofurantoin is an antibiotic used primarily for urinary tract infections. It can cause pulmonary reactions, including acute, subacute, and chronic pulmonary reactions. These reactions can involve the pleura, leading to pleural effusions and other pleural pathologies.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Metformin is not associated with causing pleural pathologies, unlike Methysergide, Bleomycin, and Nitrofurantoin, which have known risks of causing pleural and pulmonary complications.</span></p>",
      "correct_choice_id": 26053,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54893,
      "choices": [
        {
          "id": 219033,
          "text": "<p><span style=\"font-size:12.0pt;\">Orbital varix</span></p>"
        },
        {
          "id": 219034,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid eye disease</span></p>"
        },
        {
          "id": 219035,
          "text": "<p><span style=\"font-size:12.0pt;\">Retinoblastoma</span></p>"
        },
        {
          "id": 219036,
          "text": "<p><span style=\"font-size:12.0pt;\">Cavernous hemangioma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the most common cause of proptosis in a middle-aged person? (INICET MAY 2024)</span></p>",
      "unique_key": "Q3343243",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999766,
      "difficulty_level": "beginner",
      "subjects_id": [
        8
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Thyroid eye disease</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Thyroid eye disease (TED), also known as Graves' orbitopathy, is the most common cause of proptosis in middle-aged individuals. TED is an autoimmune condition associated with thyroid dysfunction, typically hyperthyroidism. The disease leads to inflammation and swelling of the extraocular muscles and increased orbital fat, causing the eyes to bulge outward (proptosis).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Orbital varix:</strong> Orbital varices are venous malformations that can cause intermittent proptosis, but they are not the most common cause. They typically become symptomatic during activities that increase venous pressure, such as straining or bending over.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Retinoblastoma:</strong> Retinoblastoma is a malignant intraocular tumor that primarily affects children. It is not a common cause of proptosis in middle-aged adults.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Cavernous hemangioma:</strong> Cavernous hemangiomas are benign vascular tumors and the most common orbital tumor in adults, but they are not the most frequent cause of proptosis. These tumors tend to grow slowly and cause progressive proptosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Intraocular tumours</strong></span></p><p><span style=\"font-size:12.0pt;\">Most common in adults : Melanoma</span></p><p><span style=\"font-size:12.0pt;\">Most common in children : Retinoblastoma</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Intraorbital tumours</strong></span></p><p><span style=\"font-size:12.0pt;\">Most common in adults : Hemangioma</span></p><p><span style=\"font-size:12.0pt;\">Most common in children : Rhabdomyosarcoma</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The most common cause of proptosis in middle-aged individuals is thyroid eye disease (TED), a condition related to thyroid dysfunction that leads to inflammation and swelling within the orbit.</span></p>",
      "correct_choice_id": 219034,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6530,
      "choices": [
        {
          "id": 26089,
          "text": "<p><span style=\"font-size:12.0pt;\">Fluconazole</span></p>"
        },
        {
          "id": 26090,
          "text": "<p><span style=\"font-size:12.0pt;\">Amphotericin B</span></p>"
        },
        {
          "id": 26091,
          "text": "<p><span style=\"font-size:12.0pt;\">Ketoconazole</span></p>"
        },
        {
          "id": 26092,
          "text": "<p><span style=\"font-size:12.0pt;\">Griseofulvin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A diabetic patient presented with rhinitis and swelling of the face. Intranasal biopsy revealed the presence of broad-based aseptate hyphae with right-angle branching. There was evidence of vascular invasion. What will be the preferred treatment for this condition?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2022)</span></p>",
      "unique_key": "Q2504228",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999958,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Amphotericin B</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The clinical presentation and biopsy findings of broad-based aseptate hyphae with right-angle branching and evidence of vascular invasion are characteristic of mucormycosis, a serious fungal infection commonly seen in diabetic patients and other immunocompromised individuals. Amphotericin B is the preferred initial treatment for mucormycosis due to its broad antifungal coverage and effectiveness against Mucorales, the group of fungi responsible for this infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Fluconazole</strong>: Fluconazole is an antifungal medication used primarily for Candida and Cryptococcus infections. It is not effective against Mucorales and therefore not suitable for treating mucormycosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Ketoconazole</strong>: Ketoconazole is another antifungal agent with a broad spectrum of action but has limited use due to its side effects and is not effective against Mucorales, making it inappropriate for mucormycosis treatment.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Griseofulvin</strong>: Griseofulvin is used for dermatophyte infections (e.g., tinea infections) and is not effective against Mucorales. It is not suitable for treating mucormycosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Treatment of Mucormycosis:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Mucormycosis is a serious fungal infection that requires prompt and aggressive treatment due to its rapid progression and high mortality rate.</span></li><li><span style=\"font-size:12.0pt;\">The mainstay of treatment is intravenous Amphotericin B, often followed by oral posaconazole or isavuconazole for maintenance therapy.</span></li><li><span style=\"font-size:12.0pt;\">Surgical debridement of infected tissue is frequently necessary.</span></li><li><span style=\"font-size:12.0pt;\">Controlling underlying conditions like diabetes is also crucial in managing mucormycosis.</span></li></ul>",
      "correct_choice_id": 26090,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 45439,
      "choices": [
        {
          "id": 181395,
          "text": "<p><span style=\"font-size:16px;\">Lippe’s loop</span></p>"
        },
        {
          "id": 181396,
          "text": "<p><span style=\"font-size:16px;\">CuT-200</span></p>"
        },
        {
          "id": 181397,
          "text": "<p><span style=\"font-size:16px;\">Nova-T</span></p>"
        },
        {
          "id": 181398,
          "text": "<p><span style=\"font-size:16px;\">ML Cu 375</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which intrauterine device (IUD) is associated with the lowest pregnancy rates? (NEET PG 2017)</span></p>",
      "unique_key": "Q5324511",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999769,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. D) ML Cu 375</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The ML Cu 375 intrauterine device is known for its very low pregnancy rates, which are typically less than 1 per 100 women years. This exceptionally low rate is due to the device's efficient design and larger copper surface area, which enhances its contraceptive efficacy. The categorization of IUDs based on pregnancy rates places ML Cu 375 in the highest efficacy group.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Lippe’s loop:</strong> Incorrect, as it belongs to an older generation of IUDs with generally higher pregnancy rates compared to more modern copper IUDs like the ML Cu 375.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. CuT-200:</strong> Incorrect, this device also has a higher pregnancy rate than ML Cu 375, making it less effective in comparison.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Nova-T:</strong> Incorrect, although it is an effective IUD, its pregnancy rates are still higher than those associated with ML Cu 375, placing it in a different efficacy category.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">ML Cu 375 is the most effective intrauterine device listed in terms of preventing pregnancy, with rates less than 1 per 100 women years.</span></p>",
      "correct_choice_id": 181398,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6533,
      "choices": [
        {
          "id": 26101,
          "text": "<p><span style=\"font-size:12.0pt;\">Evolocumab</span></p>"
        },
        {
          "id": 26102,
          "text": "<p><span style=\"font-size:12.0pt;\">Ezetimibe</span></p>"
        },
        {
          "id": 26103,
          "text": "<p><span style=\"font-size:12.0pt;\">Bempedoic acid</span></p>"
        },
        {
          "id": 26104,
          "text": "<p><span style=\"font-size:12.0pt;\">Clofibrate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a PCSK9 inhibitor?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2022)</span></p>",
      "unique_key": "Q2992308",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999942,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Evolocumab</strong></span><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Alirocumab and Evolocumab are PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. These works by inhibiting the PCSK9 enzyme which is responsible for degradation of LDL receptors in the liver. Therefore, these drugs lead to an increased number of low-density lipoprotein (LDL) receptors on liver cells and a subsequent decrease in LDL cholesterol levels in the blood. PCSK9 inhibitors are used for lowering cholesterol levels, particularly in patients with familial hypercholesterolemia or those who are at high risk for cardiovascular disease and have not adequately responded to statins.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Ezetimibe</strong>: Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine, which leads to a reduction in the total amount of cholesterol presented to the liver. It does not inhibit PCSK9.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Bempedoic Acid</strong>: Bempedoic acid is a relatively new cholesterol-lowering medication. It inhibits ATP citrate lyase, an enzyme involved in cholesterol synthesis, but it is not a PCSK9 inhibitor.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Clofibrate</strong>: Clofibrate is a fibrate used to lower lipid levels, particularly triglycerides. It works by activating peroxisome proliferator-activated receptors (PPARs) and does not inhibit PCSK9.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Evolocumab is a PCSK9 inhibitor that works by blocking the PCSK9 enzyme, leading to increased LDL receptor availability on liver cells and reduced LDL cholesterol levels in the blood.</span></p>",
      "correct_choice_id": 26101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6512,
      "choices": [
        {
          "id": 26017,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyoscine </span></span></span></p>"
        },
        {
          "id": 26018,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyproheptadine </span></span></span></p>"
        },
        {
          "id": 26019,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Levodopa </span></span></span></p>"
        },
        {
          "id": 26020,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzhexol</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient comes to the emergency room with a history of multiple episodes of vomiting. After being administered an intravenous drug for treatment, he develops abnormal movements. Which of the following medications can be used to manage his abnormal movements?</span></span> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2021)</span></span></p>",
      "unique_key": "Q2687533",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999961,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Benzhexol</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzhexol (also known as trihexyphenidyl) is an anticholinergic agent often used to treat extrapyramidal symptoms, which include abnormal involuntary movements. These symptoms can occur as a side effect of D2 blockers like antipsychotics and some antiemetics like metoclopramide that may have been used to treat the vomiting.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hyoscine</span></strong><span style=\"font-size:12.0pt\">: This is an antispasmodic and anticholinergic drug mainly used for motion sickness and gastrointestinal spasms. It is not specifically used for treating abnormal movements such as extrapyramidal symptoms.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cyproheptadine</span></strong><span style=\"font-size:12.0pt\">: This is an antihistamine and anticholinergic medication used mainly for allergic reactions. It is not primarily indicated for the treatment of abnormal movements.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Levodopa</span></strong><span style=\"font-size:12.0pt\">: This medication is primarily used for treating Parkinson&#39;s disease and is not indicated for the treatment of drug-induced abnormal movements unless those symptoms are related to Parkinson&rsquo;s disease.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Therefore, in this patient who developed abnormal movements possibly due to a drug side effect, Benzhexol would be the appropriate medication for managing his symptoms.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzhexol (trihexyphenidyl) is the drug of choice for managing extrapyramidal symptoms, which include abnormal movements induced by medications such as D2 receptor blockers.</span></span></span></p>",
      "correct_choice_id": 26020,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7039,
      "choices": [
        {
          "id": 28124,
          "text": "<p><span style=\"font-size:12pt;\">Proguanil</span></p>"
        },
        {
          "id": 28125,
          "text": "<p><span style=\"font-size:12pt;\">Sulindac</span></p>"
        },
        {
          "id": 28126,
          "text": "<p><span style=\"font-size:12pt;\">Primidone</span></p>"
        },
        {
          "id": 28127,
          "text": "<p><span style=\"font-size:12pt;\">5-Fluorouracil</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following is not a prodrug? (AIIMS MAY 2020)</span></p>",
      "unique_key": "Q9157458",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999770,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Primidone</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Prodrugs are drugs that are present in their inactive form and are converted to the active form in the body after undergoing metabolism.</span></li><li><span style=\"font-size:12pt;\">Among the given options primidone is not a prodrug. Although it produces active metabolites like phenobarbitone and phenylethylmalonamide (PEMA) but it cannot be considered as a prodrug because primidone itself is also active.</span></li></ul><p style=\"margin-left:24px;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"margin-left:24px;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong> <strong>A.</strong> <strong>Proguanil:</strong> Proguanil is a prodrug and its active metabolite is cycloguanil. It is used in the treatment and prevention of malaria.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong> <strong>C.</strong> <strong>Sulindac</strong>: Sulindac is a sulfoxide prodrug used in inflammatory diseases including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong> <strong>D. Flurouracil:</strong> Flurouracil&nbsp; is a prodrug having the active metabolite as fluorouridine monophosphate. It is an anticancer chemotherapeutic agent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Primidone is not a prodrug because it is pharmacologically active in its original form, although it also produces active metabolites. Prodrugs like Proguanil, Sulindac, and 5-Fluorouracil require metabolic activation to exert their therapeutic effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Mnemonic</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/18/screenshot-2024-07-18-101615.png\" alt=\"\" width=\"1000\" height=\"418\"></p>",
      "correct_choice_id": 28126,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6465,
      "choices": [
        {
          "id": 25829,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phase 1</span></span></span></p>"
        },
        {
          "id": 25830,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phase 2</span></span></span></p>"
        },
        {
          "id": 25831,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phase 3</span></span></span></p>"
        },
        {
          "id": 25832,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phase 4</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following phases of a clinical trial is also referred to as efficacy trial?</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (NEET PG 2019)</span></span></p>",
      "unique_key": "Q5811904",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999952,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Phase 3</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phase 3 of a clinical trial is often referred to as an efficacy trial. This is because phase 3 trials are designed to evaluate the efficacy and safety of the investigational drug or intervention in a larger and more diverse patient population. Phase 3 trials typically involve several hundred to several thousand participants and are usually randomized, controlled trials that compare the investigational drug or intervention to either a placebo or an active comparator.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Phase 1</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> trials are typically the first-in-human studies and are designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug or intervention.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Phase 2</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> trials are designed to evaluate the safety and preliminary efficacy of the investigational drug or intervention in a larger patient population than in phase 1 trials.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Phase 4</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> trials, also known as post-marketing surveillance studies, are conducted after a drug or intervention has been approved by regulatory agencies and are designed to monitor the long-term safety and effectiveness of the drug or intervention in a larger patient population than in earlier phases of the trial.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/08/screenshot-2024-10-08-132716.jpg\" style=\"height:300px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 25831,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 65028,
      "choices": [
        {
          "id": 259289,
          "text": "<p><span style=\"font-size:12.0pt;\">Trofinetide</span></p>"
        },
        {
          "id": 259290,
          "text": "<p><span style=\"font-size:12.0pt;\">Zavegepant</span></p>"
        },
        {
          "id": 259291,
          "text": "<p><span style=\"font-size:12.0pt;\">Sparsentan</span></p>"
        },
        {
          "id": 259292,
          "text": "<p><span style=\"font-size:12.0pt;\">Elacestrant</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following newly approved drugs is used in the treatment of IgA nephropathy? (Twisted PYQ)</span></p>",
      "unique_key": "Q4873910",
      "question_audio": null,
      "question_video": null,
      "map_id": 15323665,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Sparsentan</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Sparsentan is a novel dual-acting antagonist of the <strong>endothelin receptor type A</strong> and <strong>angiotensin II receptor type 1 (AT1)</strong>. It is specifically approved for the treatment of <strong>IgA nephropathy</strong>, a kidney disorder characterized by the deposition of IgA antibodies in the glomeruli, leading to proteinuria and progressive kidney damage. Sparsentan reduces proteinuria and delays progression of kidney disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A: Trofinetide</strong> – Trofinetide is approved for Rett syndrome and exhibits neuroprotective properties but has no role in IgA nephropathy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B: Zavegepant</strong> – Zavegepant is a calcitonin gene-related peptide (CGRP) antagonist approved for the treatment of migraine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D: Elacestrant</strong> – Elacestrant is a selective estrogen receptor degrader (SERD) approved for hormone receptor-positive breast cancer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Sparsentan is a new dual-action drug specifically approved for <strong>IgA nephropathy</strong>, highlighting advancements in targeted therapy for kidney diseases. Understanding its mechanism and clinical use is crucial for managing proteinuric kidney disorders.</span></p>",
      "correct_choice_id": 259291,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54837,
      "choices": [
        {
          "id": 218809,
          "text": "<p><span style=\"font-size:12.0pt;\">Main trunk of facial nerve</span></p>"
        },
        {
          "id": 218810,
          "text": "<p><span style=\"font-size:12.0pt;\">Temporal branch of facial nerve</span></p>"
        },
        {
          "id": 218811,
          "text": "<p><span style=\"font-size:12.0pt;\">Cervical branch of facial nerve</span></p>"
        },
        {
          "id": 218812,
          "text": "<p><span style=\"font-size:12.0pt;\">Parotid duct</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">After parotid surgery, the patient is found to have weakness of the lower lip on the ipsilateral side. Which of these injuries is likely to produce this? (INICET MAY 2024)</span></p>",
      "unique_key": "Q9340387",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999765,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Cervical branch of facial nerve</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In this scenario, the patient has undergone parotid surgery and subsequently developed weakness of the lower lip on the same side as the surgery (ipsilateral). This kind of symptom indicates a nerve injury.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Facial Nerve Branches:</strong> The facial nerve (cranial nerve VII) is responsible for motor control of the muscles of facial expression. It divides into several branches after it exits the stylomastoid foramen, including the temporal, zygomatic, buccal, mandibular (marginal mandibular), and cervical branches.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Cervical Branch:</strong> The cervical branch of the facial nerve, along with the marginal mandibular branch, supplies the muscles of the lower face, including those involved in the movement of the lower lip. An injury to the cervical branch could result in weakness of the lower lip, which is consistent with the patient's presentation.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Marginal Mandibular Branch:</strong> Although the marginal mandibular branch is primarily responsible for the lower lip, in cases where this specific branch is not listed as an option, the cervical branch is the closest and most accurate choice because it is part of the lower division of the facial nerve that supplies the lower lip muscles.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Main trunk of the facial nerve:</strong> Injury to the main trunk of the facial nerve would likely cause more extensive symptoms, including the inability to close the eye (Bell's phenomenon), loss of forehead wrinkling, and other signs of lower motor neuron facial paralysis, which are not mentioned in this case. Therefore, this option is less likely.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Temporal branch of the facial nerve:</strong> The temporal branch of the facial nerve innervates muscles in the upper face, such as those involved in raising the eyebrows and closing the eyelids. It does not affect the lower lip, making this option incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Parotid duct:</strong> Injury to the parotid duct would result in issues related to salivation, such as a salivary fistula, but it would not cause motor weakness of the lower lip. This option is also incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Weakness of the lower lip after parotid surgery is most likely due to injury to the cervical branch of the facial nerve. The marginal mandibular branch is the most specific, but if not listed, the cervical branch is the closest correct option</span></p>",
      "correct_choice_id": 218811,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2158,
      "choices": [
        {
          "id": 8621,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiamine</span></p>"
        },
        {
          "id": 8622,
          "text": "<p><span style=\"font-size:12.0pt;\">Niacin</span></p>"
        },
        {
          "id": 8623,
          "text": "<p><span style=\"font-size:12.0pt;\">Pyridoxal Phosphate</span></p>"
        },
        {
          "id": 8624,
          "text": "<p><span style=\"font-size:12.0pt;\">Biotin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following serves as cofactor for Glycogen phosphorylase? (AIIMS NOV 2017)</span></p>",
      "unique_key": "Q3598367",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999951,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Pyridoxal Phosphate</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Glycogen phosphorylase removes glucose as glucose- 1-phosphate from glycogen</strong> (phosphorolysis). It <strong>contains pyridoxal phosphate (PLP)</strong> as a prosthetic group. The alpha-1, 4 linkages in the glycogen are cleaved.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">PLP also acts as the coenzyme for many enzymes involved in</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Amino acid metabolism, especially <strong>transamination and decarboxylation</strong></span></li><li><span style=\"font-size:12.0pt;\"><strong>Heme</strong> synthesis</span></li><li><span style=\"font-size:12.0pt;\">Production of <strong>niacin.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A.</strong> <strong>Thiamine</strong>: Thiamine is a cofactor for enzymes involved in carbohydrate metabolism, such as pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, but it is not a cofactor for glycogen phosphorylase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Niacin</strong>: Niacin is a precursor for NAD and NADP, which are important cofactors in redox reactions, but it does not serve as a cofactor for glycogen phosphorylase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Biotin</strong>: Biotin is a cofactor for carboxylation reactions, such as those catalyzed by pyruvate carboxylase, acetyl-CoA carboxylase, and propionyl-CoA carboxylase, but it is not involved with glycogen phosphorylase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pyridoxal phosphate (PLP) is the cofactor for glycogen phosphorylase and is also involved in amino acid metabolism, heme synthesis, and niacin production.</span></p>",
      "correct_choice_id": 8623,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7128,
      "choices": [
        {
          "id": 28480,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug A decreases intestinal absorption of Drug B</span></p>"
        },
        {
          "id": 28481,
          "text": "<p><span style=\"font-size:9pt;\">﻿﻿﻿</span><span style=\"font-size:12.0pt;\">Drug A reduces first pass metabolism of Drug B</span></p>"
        },
        {
          "id": 28482,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Drug A increases the metabolism of Drug B</span></p>"
        },
        {
          "id": 28483,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug A increases renal elimination of Drug B</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The table below gives the AUC of drug B alone and that of drug B when combined with another drug A. If the p value is &lt;0.01, then which of the following statements is true? (INICET 2021)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/14/screenshot-2023-12-14-170654.jpg\" alt=\"\" width=\"700\" height=\"190\"></span></p>",
      "unique_key": "Q6184777",
      "question_audio": null,
      "question_video": null,
      "map_id": 14999941,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B.&nbsp;Drug A reduces first pass metabolism of Drug B</strong></span><br>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The area under the curve or AUC in plasma concentration vs time graph can be used as a measure of the bioavailability of a drug. The bioavailability of a given drug refers to the fraction of the given dose which reaches the systemic circulation. The greater the area under the curve or AUC, the greater is the bioavailability.</span></li><li><span style=\"font-size:12.0pt;\">From the given data, it is seen that the AUC for Drug B is less than the AUC for Drug A + Drug B. And the p value &lt;0.01 indicates that the data is statistically significant. (As the p value is &lt;0.05)</span></li><li><span style=\"font-size:12.0pt;\">So, it can be inferred that the Drug A increases the bioavailability of drug B.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">As bioavailability depends on two factors:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Absorption (Bioavailability is directly proportional to the rate of drug absorption)</span></li><li><span style=\"font-size:12.0pt;\">First Pass Metabolism (Bioavailability is inversely proportional to the rate of first pass metabolism of the drug)</span></li><li><span style=\"font-size:12.0pt;\">Therefore, it can be assumed that drug B either increase the absorption or decrease the first pass metabolism of drug A.</span></li><li><span style=\"font-size:12.0pt;\">So among the given options, best answer seem to be option B: Drug A reduces the first pass metabolism of drug B</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Drug A decreases intestinal absorption of Drug B</strong>: This statement is incorrect. If Drug A decreased the intestinal absorption of Drug B, the AUC would be lower when the drugs are combined, not higher.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Drug A increases the metabolism of Drug B</strong>: This statement is incorrect. If Drug A increased the metabolism of Drug B, the AUC would be lower when the drugs are combined.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Drug A increases renal elimination of Drug B</strong>: This statement is incorrect. If Drug A increased the renal elimination of Drug B, it would lead to a decrease in AUC, not an increase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The increase in the AUC of Drug B when combined with Drug A, with a statistically significant p value, indicates that Drug A reduces the first pass metabolism of Drug B, thereby increasing its bioavailability.</span></p>",
      "correct_choice_id": 28481,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6433,
      "choices": [
        {
          "id": 25701,
          "text": "<p><span style=\"font-size:12.0pt;\">Nucleic acid</span></p>"
        },
        {
          "id": 25702,
          "text": "<p><span style=\"font-size:12.0pt;\">Ribosome</span></p>"
        },
        {
          "id": 25703,
          "text": "<p><span style=\"font-size:12.0pt;\">Cell membrane</span></p>"
        },
        {
          "id": 25704,
          "text": "<p><span style=\"font-size:12.0pt;\">Cytoplasm</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the site of action of amphotericin B in fungi?</span><span style=\"font-size:10.5pt;\"> </span><span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p>",
      "unique_key": "Q2752560",
      "question_audio": null,
      "question_video": null,
      "map_id": 15056322,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Cell membrane</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Amphotericin B is an antifungal drug that acts by sequestering ergosterol in the cell membrane, it leads to formation of pores in the cell membrane that leads to leakage of cytosolic contents out of the cell and eventually death of the fungus.. It is the drug of choice in systemic fungal infections , mucormycosis , cryptococcal meningitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Nucleic acid:&nbsp;</strong>Amphotericin B does not target nucleic acids. Antifungal drugs that affect nucleic acid synthesis include flucytosine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Ribosome:&nbsp;</strong>Amphotericin B does not target ribosomes. Antifungal drugs that interfere with protein synthesis at the ribosomal level are not commonly used.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Cytoplasm:&nbsp;</strong>Amphotericin B acts at the cell membrane, not directly within the cytoplasm. The disruption of the cell membrane causes the loss of cytoplasmic contents.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Additional Information</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Mechanism of Action</strong>: By binding to ergosterol and forming pores, amphotericin B disrupts the integrity of the fungal cell membrane, leading to cell death.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Uses</strong>: Amphotericin B is the drug of choice for treating systemic fungal infections, mucormycosis, and cryptococcal meningitis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Amphotericin B targets the cell membrane of fungi by binding to ergosterol, forming pores that lead to leakage of cytoplasmic contents and fungal cell death. It is highly effective in treating severe systemic fungal infections.</span></p>",
      "correct_choice_id": 25703,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}